Vitamin d analogues

专利摘要:
The present invention relates to novel tri-aromatic compounds of formula (I) and methods for their preparation, and cosmetic compositions for use in human or veterinary medicine (dermatology, oncology as well as autoimmune diseases and in particular organ or tissue transplantation) or cosmetics. It relates to their use in the composition: [Formula I]
公开号:KR20020056944A
申请号:KR1020027006574
申请日:2000-11-22
公开日:2002-07-10
发明作者:베르나르동쟝-미셸；비아다띠띠보
申请人:갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨.；
IPC主号:

专利说明:

Vitamin D Analogues {VITAMIN D ANALOGUES}
[1] The present invention relates to triaromatic compounds which are vitamin D analogues as novel and useful industrial products. The invention also relates to their preparation methods and their use in pharmaceutical compositions for use in human or veterinary medicine, or alternatively in cosmetic compositions.
[2] The compounds according to the invention have significant activity in the field of cell proliferation and differentiation, and more particularly dermal (or other) diseases, inflammation and / or immunoallergic factors associated with keratinization disorders, and benign or malignant ectodermal origin It can be applied to local and systemic treatment of diseases associated with hyperproliferation of tissues (skin, epidermis, etc.). The compounds may also be used to eradicate photo-induced or age skin aging and to treat scarring disorders.
[3] The compounds according to the invention can also be used in body and hair hygiene cosmetic compositions.
[4] Vitamin D is an essential vitamin for the prevention and treatment of mineralization defects (rickets) and bone mineralization defects (osteomalacia) of bone, and certain forms of osteoporosis in the elderly. However, it is currently accepted that its function goes far beyond the regulation of bone metabolism and calcium homeostasis. Among these functions, mention may be made of action on cell proliferation and differentiation, and regulation of immune defense. These findings have led to new therapeutic approaches in the field of dermatology, oncology and autoimmune disease, and organ and tissue transplantation.
[5] Due to the long-term toxicity of these vitamins (sometimes causing fatal hypercalcemia), effective therapeutic supply has been difficult. In recent years, structural analogues of vitamin D have been synthesized, some of which possess only differentiated properties and have no action on calcium metabolism.
[6] It is an object of the present invention to provide novel compounds which are structural analogs of vitamin D and which exhibit selective activity in cell proliferation and differentiation without exhibiting any hypercalcemia properties.
[7] Another object of the present invention is to provide novel compounds which are structural analogues of vitamin D and are more easily synthesized and more economical than those previously known.
[8] Accordingly, the present invention relates to compounds which can be represented by the formula:
[9]
[10] (In the meal,
[11] -R ₁ represents a hydrogen atom, a CH ₃ radical or a radical-(CH ₂ ) _r -OR ₄ ,
[12] -R ₂ represents a radical-(CH ₂ ) _s -OR ₅ (r, s, R ₄ and R ₅ have the meanings indicated below),
[13] X-Y represents a bond selected from the bonds of the formulas a to d which can be read from left to right or vice versa:
[14]
[15]
[16]
[17]
[18] (R ₆ and W have the meanings shown below),
[19] Ar ₁ represents a ring of the formulas e to i:
[20]
[21]
[22]
[23]
[24]
[25] (R ₇ , R ₈ and R ₉ have the meanings shown below),
[26] Ar ₂ represents a ring of the formulas j to n:
[27]
[28]
[29]
[30]
[31]
[32] (R ₁₀ , R ₁₁ and R ₁₂ have the meanings shown below),
[33] R ₃ represents a radical of the formula:
[34]
[35] (t, R ₁₃ , R ₁₄ and R ₁₅ have the meanings shown below),
[36] R and s, which may be the same or different, are 1 or 2, and
[37] R ₄ and R _5, which may be the same or different, represent a hydrogen atom, an acetyl radical, a benzoyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical or a tetrahydropyranyl radical,
[38] R ₆ represents a hydrogen atom or a lower alkyl radical,
[39] W represents an NH radical which may be substituted with an oxygen or sulfur atom, a CH ₂ radical or a lower alkyl radical,
[40] R ₇ and R _10, which may be the same or different, represent a hydrogen atom or a lower alkyl radical,
[41] R ₈ , R ₉ , R ₁₁ and R ₁₂ , which may be the same or different, represent a hydrogen atom, a lower alkyl radical, a halogen atom, a radical —OR ₁₆ , a polyether radical, a CF ₃ radical, a NO ₂ radical, or one or Represents an amino radical which may be substituted with two lower alkyl radicals (R ₁₆ has the meanings indicated below),
[42] t is 0 or 1,
[43] R ₁₃ and R _14, which may be the same or different, represent a hydrogen atom, a lower alkyl radical, a cycloalkyl radical, a CF ₃ radical or a C ₂ F ₅ radical,
[44] R ₁₅ represents a hydrogen atom, an acetyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical or a tetrahydropyranyl radical,
[45] R ₁₆ represents a hydrogen atom or a lower alkyl radical).
[46] The present invention also relates to the optical and stereoisomers of the compounds of formula (I) as well as to their salts in which X-Y represents a bond of formula a and W represents an -NH- radical optionally substituted with a lower alkyl radical.
[47] When the compounds according to the invention are in salt form, they are pharmaceutically or cosmetically acceptable salts obtained by the addition of inorganic or organic acids, in particular hydrochloric acid, sulfuric acid, acetic acid, fumaric acid, hemisuccinic acid, maleic acid or mandelic acid.
[48] According to the invention, the expression "lower alkyl radical" means a straight or branched chain radical of 1 to 6 carbon atoms, preferably methyl, ethyl, isopropyl, tert-butyl and hexyl radicals.
[49] The expression "cycloalkyl radical" means a cyclic alkane radical having 3 to 6 carbon atoms. The cyclicalkyl radical is preferably selected from cyclopropyl, cyclopentyl or cyclohexyl radicals.
[50] The expression "halogen atom" preferably means a fluorine, chlorine or bromine atom.
[51] The expression "polyether radicals" means radicals of 2 to 5 carbon atoms, such as methoxymethoxy, methoxyethoxy and methoxyethoxymethoxy radicals, which contain two or more oxygen atoms.
[52] Among the compounds of the formula (I) included in the invention, mention may be made in particular of:
[53] {5- [4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[54] {2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[55] {5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[56] {2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) -2'-methylbiphenyl-3-yloxymethyl] phenyl} methanol
[57] (5- {2- [3 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
[58] {2-hydroxymethyl-5- [3 '-(1-hydroxy-1-methylethyl) -biphenyl-3-yloxymethyl] phenyl} methanol
[59] {5- [4 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[60] {5- [3 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[61] 1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) biphenyl-3-yl] -2-methyl-2-propanol
[62] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylsulfanylmethyl] -2-hydroxymethylphenyl} methanol
[63] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[64] {2-hydroxymethyl-4- [4 '-(1-hydroxy-1-propylbutyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] phenyl} methanol
[65] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[66] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[67] (4- {3- [5- (1-ethyl-1-hydroxypropyl) -2-pyridyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
[68] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[69] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[70] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[71] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2', 6'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[72] 1- {4- [3- (3,4-bis-hydroxymethyl-benzyloxy) phenyl] -2-thienyl} -1-propanol
[73] (4- {3- [4- (1-ethyl-1-hydroxypropyl) -2-thienyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
[74] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy] -2-hydroxymethylphenyl} methanol
[75] 1- [3 '-(3,4-bis-hydroxymethyl-phenoxymethyl) -2-methylbiphenyl-4-yl] -1-propanol
[76] {4- [4 '-(1-ethyl-1-hydroxypropyl) -3'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[77] {5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-4-yloxymethyl] -2-hydroxymethylphenyl} methanol
[78] {4- [2'-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[79] 1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) -2-methyl-biphenyl-4-yl] -2,2-dimethyl-1-propanol
[80] 1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) -2-methylbiphenyl-4-yl] -2-methyl-1-propanol
[81] {2-hydroxymethyl-4- [methyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[82] [5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[83] (5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[84] [5- (2- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[85] (5- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[86] [5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -4-methyl-2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[87] (5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -4-methyl-2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[88] [2-hydroxymethyl-5- (2- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
[89] (2-hydroxymethyl-5- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
[90] [5- (2- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[91] (5- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[92] [2-hydroxymethyl-5- (2- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
[93] (2-hydroxymethyl-5- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
[94] [5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[95] (5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[96] [5- (2- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[97] (5- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[98] [2-hydroxymethyl-5- (2- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienyl} ethyl) phenyl] methanol
[99] (2-hydroxymethyl-5- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienylmethoxy} phenyl) methanol
[100] [5- (2- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) -phenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[101] (5- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[102] [5- (2- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[103] (5- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[104] [5- (2- {4- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[105] (5- {4- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[106] [5- (2- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -5-methyl-2-thienyl} -ethyl) -2-hydroxymethylphenyl] methanol
[107] (5- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -5-methyl-2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[108] [2-hydroxymethyl-5- (2- {4- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
[109] (2-hydroxymethyl-5- {4- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl] methanol
[110] [5- (2- {4- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
[111] (5- {4- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[112] [2-hydroxymethyl-5- (2- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
[113] (2-hydroxymethyl-5- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
[114] {5- [2'-ethyl-4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[115] {5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-isopropyl-6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[116] {5- [2'-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[117] {5- [ethylmethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[118] {2-hydroxymethyl-5- [2'-isopropyl-6-methyl-4 '-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl) biphenyl- 3-yloxymethyl] phenyl} methanol
[119] {5- [dimethylethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[120] {5- [6-ethyl-4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[121] {5- [4 '-(1-ethyl-1-hydroxypropyl) -6-methoxy-2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[122] {5- [6-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[123] {5- [ethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[124] (2-Hydroxymethyl-5- [6-methoxy-2'-methyl-4 '-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl) biphenyl- 3-yloxymethyl] phenyl} methanol
[125] {5- [dimethylethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[126] (5- {2- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
[127] (5- {2- [dimethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
[128] (5-{[4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-ylamino] methyl} -2-hydroxymethylphenyl) methanol
[129] (5-{[dimethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-ylamino] methyl} -2-hydroxymethylphenyl) methanol
[130] [5-({[4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yl] methylamino} methyl) -2-hydroxymethylphenyl] methanol
[131] [5-({[dimethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yl] methylamino} methyl) -2-hydroxymethylphenyl] methanol.
[132] According to the invention, more particularly preferred compounds of formula (I) are those which satisfy one or more, preferably all of the following conditions:
[133] R ₁ represents a CH ₃ or CH ₂ 0H radical,
[134] R ₂ represents a CH ₂ 0H radical,
[135] X-Y represents a bond of formula a or c,
[136] R ₃ represents the radical C (R ₁₃ ) (R _l4 ) OH.
[137] The subject of the invention is also a process for preparing the compounds of formula (I).
[138] 1 to 5 show reaction schemes that can be used to prepare the compounds according to the invention.
[139] Accordingly, the compound of formula (a) is preferably a halo compound, preferably a bromo compound (1) and a phenolic (Y = OH), thiophenolic (Y = SH) or aniline (Y = NH-COO-tert- Butyl) derivative (3) can be obtained by reaction in a solvent, such as acetone or methyl ethyl ketone, in the presence of a base such as K ₂ CO ₃ (FIG. 1).
[140] The compounds of formula (a) are also halo compounds, preferably bromo compounds (1) and phenolic (Y = OH), thiophenolic (Y = SH) or aniline (Y = NH-COO-tert-butyl ) Sodium or potassium salts of derivative (3) can be obtained by reacting in a solvent, for example dimethylformamide (DMF) (FIG. 1).
[141] The compound of the formula (b) may be a benzoic acid derivative (2) and a phenolic (Y = OH), thiophenolic (Y = SH) or aniline (Y = NH ₂ ) derivative (3) as a solvent, for example dichloromethane. Or in tetrahydrofuran (THF), by reaction in the presence of carbonyldiimidazole or dicyclohexylcarbodiimide (FIG. 1).
[142] Compounds of formula (b) also contain benzoyl chloride (obtained by reacting benzoic acid derivative (2) with thionyl chloride or oxalyl chloride) and phenolic (Y = OH), thiophenolic (Y = SH) or aniline (Y = NH ₂ ) derivative (3) can be obtained by reaction in a solvent, such as dichloromethane or tetrahydrofuran (THF), in the presence of a base such as triethylamine (FIG. 1).
[143] Compounds (1), (2) and (3) can be obtained according to the scheme shown in FIGS. 2, 3 and 4. The process for the preparation of compounds (1) and (2) has the advantage that the number of preparation steps is limited.
[144] In FIG. 2, (a) shows the reaction with BH ₃ in dioxane, (b) shows the reaction with CH ₃ OCH ₂ Cl in the presence of sodium hydride in a dimethylformamide solvent, and (c) shows tetrahydrofuran Reaction with n-butyllithium in the presence of heavy CO ₂ , (d) shows reaction with dimethylformamide after reaction with n-butyllithium in tetrahydrofuran, and (e) methanol-tetrahydrofuran The reduction reaction with sodium borohydride in the solvent is shown, and (f) represents the reaction with carbon tetrabromide in the presence of triphenylphosphine in dichloromethane solvent.
[145] In FIG. 3, (a) shows the reaction with BH ₃ in dioxane, (b) shows the reaction with methanol in the presence of sulfuric acid, and (c) shows tC ₄ H in the presence of imidazole in dimethylformamide solvent. ₉ shows the reaction with (CH ₃ ) ₂ SiCl, (d) shows the reaction with LiAlH ₄ in ether, (e) shows the reaction with benzoyl chloride in the presence of triethylamine in tetrahydrofuran, (f ) Represents the reaction with (C ₄ H ₉ ) ₄ NF in tetrahydrofuran and (g) represents the reaction with carbon tetrabromide in the presence of triphenylphosphine in dichloromethane solvent.
[146] Derivative (3) can be obtained according to the scheme shown in FIG. The boric acid derivative (4) and the indoaryl derivative (5) are subjected to Suzuki type reaction in the presence of a catalyst such as tetrakis (triphenylphosphine) palladium and reacted with an alkylmagnesium or cycloalkylmagnesium halide or alkyllithium. An ester derivative (6) which is converted to the derivative (3) is obtained.
[147] The compound of formula I (c) is obtained by a Horner-Emmons reaction between phosphonate derivative 8 (obtained from the corresponding benzyl bromide by the Arbuzov reaction) and benzaldehyde 7 Can be (FIG. 5).
[148] Compounds of formula I (d) can be obtained from compound I (c) by hydrogenating a double bond in the presence of palladium on charcoal.
[149] Compounds of formula (I) also contain acetylene derivatives (9) (obtained by reacting benzaldehyde (7) by Corey-Fuchs reaction) with triflate derivatives (X = OSO ₂ CH ₃ ) or iodine It can also be obtained by reacting Sonogashira with a derivative (X = I) 10 in the presence of a transition metal catalyst such as Pd (Cl) ₂ (PPh ₃ ) ₂ and CuI in a solvent such as triethylamine. (FIG. 6).
[150] Compounds of formula (I) have a biological activity similar to vitamin D, in particular the transactivating properties of the vitamin D response element (VDRE), such as agonist or antagonist activity on receptors of vitamin D or derivatives thereof. The expression "vitamin D or its derivatives" means, for example, derivatives of vitamin D ₂ or D ₃ , in particular 1,25-dihydroxyvitamin D ₃ (calcitriol).
[151] The agonist activity associated with receptors of vitamin D or derivatives thereof can be demonstrated "in vitro" by methods known in the field of gene transcription research (Hansen et al., The Society for Investigative Dermatologie, vol. 1, No. 1, 1996. 4.).
[152] As an example, the VDR agonist activity is -1399 to + of a rat 24-hydroxylase promoter cloned upstream of a discovery vector for human VDR receptor, and a frame encoding the chloramphenicol-acetyl-transferase (CAT) gene. The reporter plasmid p240Hase-CAT comprising 76 regions can be coated and tested on HeLa cell lines. After 18 hours of coverage, the test product is added to the medium. After 18 hours of treatment, CAT activity assays in cell lysates are performed by ELISA test. Results are expressed as percentage of the effect normally observed with 10 ⁻⁷ M calcitriol.
[153] Agonist activity can also be ascertained by determining the dose (AC50) needed to reach 50% of the maximum activity of the product in the co-fection system.
[154] The biological activity of vitamin D analogs can also be measured by the product's ability to inhibit the proliferation of normal human keratinocytes (NHK in culture). The product is added to NHK incubated under conditions that promote the state of proliferation. The product is left to contact the cells for 5 days. Proliferating cell numbers are measured by incorporation of bromodeoxyuridine (BRdU) into DNA.
[155] The vitamin D receptor agonist activity of the compounds of the present invention can also be assessed "in vivo" by induction of 24-hydroxylase in SKH mice (Voorhees et al., 1997, 108: 513-). 518).
[156] The subject of the invention is also a compound of formula I as described above, as a pharmaceutical product.
[157] The compounds according to the invention are particularly suitable for the following therapeutic fields:
[158] 1) Treatment of skin diseases associated with keratin disorders occurring on differentiation and proliferation, in particular of simple acne, scrim, multinucleated leukocytes, injections, crystalline cystic acne, coagulated acne, senile acne and secondary acne, such as daylight, drug associated or occupational acne cure,
[159] 2) other types of keratinizing disorders, especially ichthyosis, young condition, Darier's disease, palmar keratosis, leukoplasias and vitiligo condition, and skin or mucous membranes (buccal) cure,
[160] 3) other dermatological diseases of inflammatory immunoallergic factors, with or without cell proliferation, in particular all forms of psoriasis that are skin, mucous or subgingival psoriasis, and psoriasis rheumatism, or alternatively skin atopic, such as eczema or respiratory atopic or alternatively gingival hyperplasia Treatment,
[161] 4) benign or malignant, and all skin or epidermal proliferation of viral or other origin, such as proliferation that can be induced by vulgar warts, squamous warts and warty epidermal dysplasia, oral or flowering papillomas, T lymphomas and ultraviolet radiation , In particular the treatment of any precancerous skin lesions, such as keratinocytes, as well as basocellular and spinocellular epithelial tumors,
[162] 5) treatment of other dermatological diseases, such as immune dermatitis, such as erythematous lupus, immune bullous, and collagen diseases such as scleroderma,
[163] 6) treatment of dermatological or general ailments of immunological factors,
[164] 7) eradication of sebaceous disorders such as acne or simple seborrhea,
[165] 8) treatment of skin disorders by exposure to UV radiation, as well as treatment of skin aging that is photoinduced or age aging and eradication, actinic keratosis and pigmentation, or any indication associated with age or ray aging,
[166] 9) prevention or treatment of scarring disorders, or prevention and treatment of stretch marks,
[167] 10) treatment of inflammatory diseases such as arthritis,
[168] 11) treatment of skin diseases or any disease of overall viral origin, such as Kaposi's syndrome,
[169] 12) treatment of certain ophthalmic disorders, in particular keratosis,
[170] 13) treatment of cancer or precancerous conditions that may be present or induced by vitamin D receptors, including but not limited to, for example, breast cancer, leukemia, myelodysplastic syndromes and lymphomas, epithelial epithelial cells and gastrointestinal carcinomas, melanoma and osteosarcoma or prevention,
[171] 14) prevention or treatment of alopecia of various origins, especially alopecia with chemotherapy or radiation,
[172] 15) immune diseases such as autoimmune diseases such as type 1 diabetes, multiple sclerosis, lupus and lupus type diseases, asthma, glomerulonephritis, selective dysfunction of the immune system such as AIDS, or immune rejection such as kidney, heart, Prevention of bone marrow, liver, pancreatic islet, pancreatic or skin graft rejection, or graft-versus-host disease,
[173] 16) treatment of endocrine diseases in which vitamin D analogs can modify hormone secretion, eg, increased insulin secretion or selective inhibition of parathyroid hormone secretion, eg, in chronic renal failure and secondary hyperparathyroidism,
[174] 17) treatment of diseases characterized by abnormal treatment of intracellular calcium, and treatment and prevention of conditions involving calcium metabolism, such as muscle ischemia (myocardial infarction),
[175] 18) treatment or prevention of vitamin D deficiency and other mineral homeopathic diseases in plasma and bone, such as rickets, osteomalacia, osteoporosis, renal dystrophy and parathyroid dysfunction, especially in postmenopausal women,
[176] 19) Treatment of cardiovascular diseases such as arteriosclerosis or hypertension, as well as insulin independent diabetes.
[177] In the therapeutic field mentioned above, the compounds according to the invention are advantageously combined with retinoids, corticoids or estrogens, or with antioxidants, α-hydroxy or α-keto acids or derivatives thereof, potassium channel blockers, Alternatively, it may be used in combination with other pharmaceutical products known to interfere with the immune system (eg cyclosporin, FK 506, glucocorticoids, monoclonal antibodies, cytokines or growth factors, etc.).
[178] The term "retinoid" means a natural or synthetic RAR- or RXR-receptor ligand.
[179] The expression “free-radical scavenger” means, for example, α-tocopherol, superoxide dismutase, ubiquinol or certain metal-chelating agents.
[180] The expression “α-hydroxy or α-keto acid or derivative thereof” is, for example, lactic acid, malic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, glyceric acid, ascorbic acid and salicylic acid derivatives, as well as salts thereof. , Amide or ester thereof.
[181] The expression "potassium-channel blocker" means, for example, minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof.
[182] Also subject of the invention are pharmaceutical compositions containing at least one compound of the formula (I) as defined above.
[183] Accordingly, the subject of the present invention is also the above pharmaceutical composition especially for the treatment of the abovementioned diseases.
[184] The compounds according to the invention can be administered via the oral, parenteral, topical or ocular route.
[185] By oral route, the pharmaceutical composition may be in the form of tablets, gel capsules, dragees, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres, or fatty vehicles or polymer vehicles that allow controlled release. Can be. Via the parenteral route, the composition may be in the form of a solution or suspension for infusion or injection. The compounds according to the invention are generally administered in one to three intakes of a daily dose of about 0.001 μg / kg body weight to 1000 μg / kg body weight, preferably about 0.01 μg / kg body weight to 100 μg / kg body weight.
[186] Via the topical route, the pharmaceutical compositions based on the compounds according to the invention are for the treatment of the skin and mucous membranes, in the form of ointments, creams, emulsions, plasters, powders, infusion pads, solutions, gels, sprays, lotions or suspensions. to be. They may also be in the form of microspheres or nanospheres, or fatty vehicles or polymer vehicles that allow controlled release, or polymer patches and hydrogels. The topical route composition may be in anhydrous form or in aqueous form depending on the clinical indication.
[187] Through the ocular pathway, these are mainly eye drops.
[188] The topical-path or ocular-path composition preferably contains at least one of the compounds of formula (I) as defined above in a concentration of preferably 0.0001% to 5%, more preferably 0.001% to 1% by weight of the total weight of the composition. do.
[189] The compounds of formula (I) according to the invention are also useful in the field of cosmetics, in particular in body and hair hygiene, in particular in the treatment of acne skin, promoting hair growth, preventing hair loss, eradicating seborrheic appearance of the skin or hair, protecting against the harmful effects of sunlight or physiology. It can be applied to the treatment of scientifically dry skin, the prevention and / or eradication of photoinduced or age aging.
[190] In the field of cosmetics, the compounds according to the invention are advantageously combined with retinoids, corticoids, or with free-radical scavengers, α-hydroxy or α-keto acids or derivatives thereof, or alternatively ion-channel blockers, It can be used in combination with various products which are taken in combination with the compounds of the invention as defined above.
[191] Accordingly, the present invention relates to cosmetic compositions which contain at least one compound of the formula (I) as defined above in a cosmetically acceptable support. The cosmetic composition may in particular be in the form of creams, emulsions, lotions, gels, microspheres or nanospheres or fatty vehicles or polymer vehicles, soaps or shampoos.
[192] The concentration of the compound of formula I in the cosmetic composition may be from 0.001% to 3% by weight relative to the total weight of the composition.
[193] In addition, the pharmaceutical and cosmetic compositions according to the invention may comprise additives which are inert or pharmaceutically or cosmetically active, or combinations of such additives, in particular: wetting agents; Bleaching agents such as hydroquinone, azelaic acid, caffeic acid or kojic acid; Softeners; Humectants such as glycerol, PEG 400, thiamorpholinone and derivatives or urea thereof; Anti-sebum agents, anti-acne agents such as S-carboxymethylcysteine or S-benzylcysteamine and salts and derivatives thereof, or benzoyl peroxide; Antibiotics such as erythromycin and its esters, neomycin, clindamycin and its esters, tetracycline; Antifungal agents such as ketoconazole or poly-4,5-methylene-3-isothiazolinone; Hair growth promoters such as minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) and derivatives thereof, diazoxide (7-chloro-3-methyl-1,2,4-benzothiadia Gin 1,1-dioxide) and phenytoin (5,4-diphenylimidazolidine-2,4-dione); Nonsteroidal anti-inflammatory agents; Carotenoids, in particular β-carotene; Anti-psoriasis agents such as anthraline and derivatives thereof, and finally, eicosa-5,8,11,14-tetrainoic acid and eicosa-5,8,11-triinoic acid, and esters and amides thereof. Can be.
[194] In addition, the compositions according to the invention can be used in flavor enhancers, preservatives such as para-hydroxybenzoic acid esters, stabilizers, moisturizing regulators, pH regulators, osmotic regulators, emulsifiers, UV-A and UV-B blockers, antioxidants such as α- Tocopherol, butylhydroxyanisole or butylhydroxytoluene.
[195] Now, various examples of preparation of the active compounds of formula (I) according to the invention and various specific formulations based on these compounds, and test examples for evaluating the biological activity of the compounds of formula (I) according to the invention, are by way of example and not limiting. Will be represented.
[196] Example 1
[197] {5- [4 '(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[198] a) dimethyl 4-hydroxymethylphthalate
[199] 1,2,4-benzenetricarboxylic anhydride (50 g, 260 mmol) is dissolved in 800 mL of anhydrous dioxane. BH ₃ .THF (260 mmol, 1 equiv) is added dropwise through a dropping funnel over a period of about 1 hour 30 minutes at room temperature. After stirring is maintained for 12 hours, the reaction medium is poured into a mixture containing 600 mL of saturated ammonium chloride solution and 2 L of dichloromethane. After standing to separate the phases, the organic phase is dried and the solvent is distilled off under reduced pressure. The residue obtained is then dissolved in 1 L of methanol and 5 mL of sulfuric acid is added followed by heating to reflux. After refluxing for 18 hours, the reaction medium is cooled to room temperature and poured directly into a water / ethyl ether mixture (1 L / 2 L). After standing to separate the phases, the aqueous phase is reextracted into two fractions of ethyl ether (about 700 mL), then the organic phases are combined, dried and concentrated under reduced pressure. A triester-diester / alcohol mixture containing 65% of the desired product is obtained in 80% yield.
[200] b) dimethyl 4- (tert-butyldimethylsilanyloxymethyl) phthalate
[201] The resulting mixture containing about 135 mmol of the desired product is dissolved in 400 mL of anhydrous DMF. Then tert-butyldimethylsilyl chloride (22.5 g, 150 mmol) is added in a single fraction. Then 13.5 g (195 mmol) of imidazole total is added in 3 fractions (slightly exothermic). The reaction medium is stirred for 36 hours and concentrated under reduced pressure. The residue is then dissolved in 500 mL of ethyl ether and then filtered to remove the imidazole hydrochloride formed. The salts are washed with two 150 mL portions of ethyl ether and the organic phases are combined, dried and concentrated under reduced pressure. The residue obtained is then purified by chromatography on a silica column. The first product collected (eluent: 10 EtOAc / 90 heptanes) is the desired dimethyl 4- (tert-butyldimethylsilanyloxymethyl) phthalate. 87% yield, total yield from starting acid: 45%
[202] c) [5- (tert-butyldimethylsilanyloxymethyl) -2-hydroxymethylphenyl] methanol
[203] The diester obtained (75 g, 220 mmol) is dissolved in 1 L of ethyl ether and cooled to 0 ° C. under nitrogen pressure. After careful addition of 5 g of LiAlH ₄ 5, the mixture is heated to 50 ° C. After stirring for 1 hour 30 minutes, the reaction medium is cooled back to 0 ° C. and then successively treated with 20 mL of water, 20 mL of 15% NaOH and then 60 mL of water. The reaction medium is stirred for 30 minutes until the gray aluminum salt disappears completely and its precipitation, a white flake, occurs. The medium is then filtered off, then the salts are rinsed with 3 fractions of ethyl ether (200 mL) and the organic phases are combined, dried and concentrated under reduced pressure. The product obtained yields 97%.
[204] d) 2-benzoyloxymethyl-4- (tert-butyldimethylsilanyloxymethyl) benzyl benzoate
[205] The crude diol (60 g, 212 mmol) obtained above is dissolved in 600 mL of dry THF and cooled to 0 ° C. Then 74 mL (530 mmol) of triethylamine are added followed by 52 mL (448 mmol) of benzoyl chloride. DMAP (500 mg) is then added in a single fraction and the mixture is stirred at 0 ° C. for 30 minutes and then at room temperature for 12 hours. The reaction medium is then filtered to remove the precipitated triethylammonium salt, the salt is rinsed with two portions of 200 mL of ethyl acetate, and then the mixture of organic phases is concentrated under reduced pressure. The obtained residue is taken up in dichloromethane and the organic phase is washed with saturated ammonium chloride solution followed by water. After drying over magnesium sulfate and concentration under reduced pressure, a dark yellow residue is obtained, which will be used without further modification for the next step.
[206] e) 2-benzoyloxymethyl-4-hydroxymethylbenzyl benzoate
[207] The residue obtained is dissolved in 600 mL of ethyl acetate and 220 mL of tetrabutylammonium fluoride solution (1 M in THF) is added in a single fraction. After stirring for 30 minutes at room temperature, the reaction medium is poured into 1 L of saturated ammonium chloride solution. After separation, the aqueous phase is reextracted with 500 mL of ethyl acetate and the organic phases are combined, dried and evaporated. The product is then purified by chromatography on silica column (30 ethyl acetate / 70 heptanes). A white solid is obtained (m. P .: 91-93 ° C.).
[208] f) (3,4-bis-benzoyloxymethyl) benzyl bromide
[209] The alcohol (65 g, 172 mmol) is dissolved in 350 mL of dichloromethane and CBr ₄ (67.7 g, 202 mmol) is added. The medium is cooled to 0 ° C. and a solution of triphenylphosphine (53 g, 202 mmol) in 250 mL of dichloromethane is added dropwise. The reaction medium is then warmed to room temperature and stirred for 2 hours. The medium is then treated with 500 mL of water and extracted with dichloromethane. After drying and concentrating the organic phase, the product is purified by chromatography (eluent: CH ₂ Cl ₂ / EtOAc) to give a white solid (mp: 83 ° C.) in 93% yield.
[210] g) 3-methoxymethoxyphenylboric acid
[211] 10 g (57.8 mmol) of 3-bromophenol are dissolved in 150 mL of anhydrous DMF. Then 2.55 g (63.6 mmol) of 60% sodium hydride are added and the reaction medium is stirred for 1 hour. Then 4.83 mL (63.6 mmol) of methoxymethyl chloride are added dropwise and the reaction mixture is stirred for 1 hour. After treatment with saturated sodium chloride solution, extraction with ethyl ether and evaporation of the solvent from the organic phase, the resulting residue is dissolved in 200 mL of dry THF. The mixture is cooled to −78 ° C. and then 25.4 mL (63.6 mmol) of 2.5 M butyllithium solution are added. After stirring at −78 ° C. for 1 hour, 15 mL (65 mmol) of triisopropyl borate are added dropwise. The reaction medium is stirred for 1 hour and then warmed to room temperature and then treated with 1N hydrochloric acid solution. The medium is then extracted with ethyl acetate and then the organic phases are combined, dried and concentrated under reduced pressure. Slurry in heptane and then concentrate to give a brown solid (m. P .: 45 ° C., m = 5.8 g; Y = 67%).
[212] (h) ethyl 3'-hydroxybiphenyl-4-carboxylate
[213] 2 g (13.3 mmol) of 3-methoxymethoxyphenylboric acid and 1.86 mL (11 mmol) of ethyl 4-iodobenzoate are dissolved in 20 mL of DME. 13.3 mL (26.6 mmol) of 2 M potassium carbonate solution is then added and the reaction medium is degassed with argon for 10 minutes. Then 640 mg of Pd (PPh ₃ ) ₄ are added and the mixture is heated at 90 ° C. for 14 hours. After treatment with saturated ammonium chloride solution, extraction with ethyl acetate and then drying and evaporation of the solvent from the organic phase dissolve the residue in 25 mL of anhydrous methanol and 0.5 mL of sulfuric acid is added. The reaction medium is refluxed for 15 hours and then cooled to final treatment by addition of water. After extraction with ethyl acetate, the organic phase is left to stand to separate, dried and concentrated under reduced pressure. After purification by chromatography on a silica column, a colorless oil is obtained (m = 2 g; Y = 75%).
[214] (i) methyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-carboxylate
[215] 1 g (4.1 mmol) of ethyl 3'-hydroxybiphenyl-4-carboxylate, 1.98 g (4.5 mmol) of 3,4-bis (benzoyloxymethyl) benzyl bromide and 600 mg of potassium carbonate are 2-butanone 40 Dissolve in mL. The mixture is refluxed (80 ° C.) and stirred for 4 h. After cooling, the reaction medium is filtered and then concentrated under reduced pressure. After the residue is purified by chromatography on a silica column, a white solid is obtained (m. P. = 71-72 ° C) (m = 2.18 g; Y = 88%).
[216] j) {5- [4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[217] After 700 mg (1.16 mmol) of ethyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-carboxylate are dissolved in 30 mL of anhydrous THF, the mixture is cooled to 0 ° C. Then, 3.1 mL (9.3 mmol) of ethylmagnesium bromide solution (3M) is added, and then the reaction medium is allowed to warm to room temperature and stirred for 1 hour. After treatment with saturated ammonium chloride solution and extracted with ethyl acetate, the combined organic phases are dried and concentrated under reduced pressure. After purification by chromatography on a silica column, a colorless oil is obtained (m = 385 mg; Y = 82%).
[218]
[219] Example 2
[220] {2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[221] In a similar manner as in Example 1 (j), ethyl 3 '[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-carboxylate (700 mg, 1.16 mmol) was added to a methylmagnesium bromide solution ( 3M) (3.1 mL, 9.3 mmol) and purified by chromatography on a silica column give a white solid (mp = 88-90 ° C.) (m = 405 mg, Y = 93%).
[222]
[223] Example 3
[224] {5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[225] (a) ethyl 3'-hydroxy-2-methylbiphenyl-4-carboxylate
[226] In a similar manner as in Example 1 (h), 2 g (13.3 mmol) of 3-methoxymethoxyphenylboric acid was reacted with 1.9 g (8.9 mmol) of 3-methyl 4-bromobenzoic acid to give 1.6 g of the desired product ( 74%) is obtained.
[227] (b) methyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate
[228] In a similar manner as in Example 1 (i), 1.6 g (6.6 mmol) of ethyl 3'-hydroxy-2-methylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl bromide 3.47 g (7.9 mmol) to give 3.7 g (94%) of methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate. To obtain.
[229] (c) {5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[230] In a similar manner as in Example 1 (j), methyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate (800 mg, 1.33 mmol) was added. Reaction with ethylmagnesium bromide solution (3M) (3.6 mL, 10 mmol) and then purified by chromatography on a silica column to give a colorless oil (m = 475 mg; Y = 85%).
[231]
[232] Example 4
[233] {2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) -2'-methylbiphenyl-3-yloxymethyl] phenyl} methanol
[234] In a similar manner as in Example 3 (c), methyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate (800 mg, 1.33 mmol) was added. Treatment with methylmagnesium bromide solution (3M) (3.6 mL, 10 mmol) followed by chromatography on a silica column yields a white solid (mp 45 ° C.) (m = 430 mg; Y = 83%).
[235]
[236] Example 5
[237] (5- {2- [3 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
[238] (a) ethyl 3'-hydroxybiphenyl-3-carboxylate
[239] In a similar manner as in Example 1 (h), 2 g (13.3 mmol) of 3-methoxymethoxyphenylboric acid were reacted with 1.83 mL (11 mmol) of ethyl 3-iodobenzoate to give 1.9 g of the desired ethyl ester ( 72%) is obtained.
[240] (b) ethyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-carboxylate
[241] In a similar manner as in Example 1 (i), 1 g (4.1 mmol) of ethyl 3'-hydroxybiphenyl-3-carboxylate was added 1.98 g (4.5 mmol) of 3,4-bis (benzoyloxymethyl) benzyl bromide ) To 2.1 g (85%) of ethyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-carboxylate.
[242] (c) (5- {2- [3 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
[243] In a similar manner as in Example 1 (j), ethyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-carboxylate (400 mg, 0.66 mmol) was added to ethylmagnesium bromide solution. Treatment with (3M) (1.8 mL, 5.3 mmol) and purification by chromatography on silica column yields a colorless oil (m = 217 mg; Y = 81%).
[244]
[245] Example 6
[246] {2-hydroxymethyl-5- [3 '-(1-hydroxy-1-methylethyl) biphenyl-3-yloxymethyl] phenyl) methanol
[247] In a similar manner as in Example 5 (c), ethyl 3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-carboxylate (380 mg, 0.63 mmol) was added to methylmagnesium bromide 3.0 Treatment with M solution (1.7 mL, 5 mmol) and purification by chromatography on a silica column give a white solid (mp 103-104 ° C.) (m = 224 mg; Y = 94%).
[248]
[249] Example 7
[250] {{5- [4 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl } methanol
[251] (a) ethyl (3'-hydroxybiphenyl-4-yl) acetate
[252] In a similar manner as in Example 1 (h), 543 mg (3.6 mmol) of 3-methoxymethoxyphenylboric acid was reacted with 700 mg (2.4 mmol) of ethyl 4-iodophenylacetate to give 630 mg of the desired ethyl ester ( 68%) is obtained.
[253] (b) ethyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-yl} acetate
[254] In a similar manner as in Example 1 (i), 360 mg (1.4 mmol) of ethyl (3'-hydroxybiphenyl-4-yl) acetate were added to 676 mg (1.5 mg of 3,4-bis (benzoyloxymethyl) benzyl bromide mmol) to give 810 mg (94%) of ethyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-yl} acetate.
[255] (c) {{5- [4 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[256] In a similar manner as in Example 1 (j), ethyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-4-yl} acetate (400 mg, 0.66 mmol) was added 3.0 M ethyl. Treatment with magnesium bromide solution (1.8 mL, 5.3 mmol) and purification by chromatography on a silica column give a colorless oil (m = 236 mg; Y = 85%).
[257]
[258] Example 8
[259] {5- [3 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[260] (a) Methyl (3'-hydroxybiphenyl-3-yl) acetate
[261] In a similar manner as in Example 1 (h), 2 g (13.3 mmol) of 3-methoxymethoxyphenylboric acid was reacted with 2 g (9.3 mmol) of 3-bromophenylacetic acid to give 1.6 g (72%) of methyl ester. ) Is obtained.
[262] (b) methyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-yl} acetate
[263] In a similar manner as in Example 1 (i), 1 g (4.1 mmol) of methyl (3'-hydroxybiphenyl-3-yl) acetate was added 2 g (4.5) of 3,4-bis (benzoyloxymethyl) benzyl bromide mmol) to give 2.2 g (91%) of methyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-yl} acetate.
[264] (c) {5- [3 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[265] In a similar manner as in Example 1 (j), methyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-yl} acetate (700 mg, 1.16 mmol) was added 3.0 M ethyl. Treatment with magnesium bromide solution (3.1 mL, 9.3 mmol) and purification by chromatography on a silica column give a colorless oil (m = 419 mg; Y = 86%).
[266]
[267] Example 9
[268] 1- [3 '-(3,4-bis-hydroxymethylbenzyloxy) biphenyl-3-yl] -2-methylpropan-2-ol
[269] In a similar manner as in Example 8 (c), methyl {3 '-[3,4-bis (benzoyloxymethyl) benzyloxy] biphenyl-3-yl} acetate (700 mg, 1.13 mmol) was added to ethylmagnesium bromide. Treatment with solution (3M) (3.1 mL, 9.3 mmol) and purification by chromatography on a silica column yields a colorless oil (m = 419 mg; Y = 92%).
[270]
[271] Example 10
[272] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylsulfanylmethyl] -2-hydroxymethylphenyl} methanol
[273] a) dimethyl 4- (3-bromophenylsulfanylmethyl) phthalate
[274] 5 g (26 mmol) of 3-bromothiophenol and 9.2 g (32 mmol) of dimethyl 4-bromomethylphthalate are dissolved in 150 mL of 2-butanone. 4 g (29 mmol) of potassium carbonate are added and the mixture is refluxed and stirred for 2 hours. The reaction medium is then filtered and concentrated under reduced pressure to purify the residue by chromatography on a silica column. Yellow oil (10 g) is obtained in 100% yield.
[275] b) [5- (3-bromophenylsulfanylmethyl) -2-hydroxymethylphenyl] methanol
[276] Dimethyl 4- (3-bromophenylsulfanylmethyl) phthalate (10 g, 26 mmol) is dissolved in 120 mL of dry THF. Then 2.2 g (100 mmol) of lithium borohydride are slowly added and the reaction medium is refluxed for 12 h. After cooling the solution is treated with saturated ammonium chloride solution and the reaction medium is extracted with ethyl acetate. The organic phases are combined, dried and concentrated under reduced pressure. The residue is purified by chromatography on a silica column to give a colorless oil (7.8 g, Y = 89%).
[277] j) [2-hydroxymethyl-5- (3-tributylstannylphenylsulfanylmethyl) phenyl] methanol
[278] 6.2 g (18 mmol) of [5- (3-bromophenylsulfanylmethyl) -2-hydroxymethylphenyl] methanol are dissolved in 120 mL of anhydrous toluene. After the mixture was degassed with argon for 10 minutes, 18 mL (36 mmol) of hexabutylditin and 416 mg (0.36 mmol) of Pd (PPh ₃ ) ₄ were added. The reaction medium is then stirred at 120 ° C. for 48 hours, cooled, treated with saturated ammonium chloride solution and extracted with ethyl acetate. The combined organic phases are dried and concentrated under reduced pressure. The residue is purified by chromatography on a silica column (eluent: pure heptane) to give a yellow oil (m = 3.35 g; Y = 34%).
[279] k) methyl 3 '-(3,4-bis-hydroxymethyl-benzylsulfanyl) -2-methylbiphenyl-4-carboxylate
[280] 1.67 g (3 mmol) of [2-hydroxymethyl-5- (3-tributylstannylphenylsulfanylmethyl) phenyl] methanol are dissolved in 30 mL of toluene and 5 mL of DME. 970 mg (4.5 mmol) of 4-bromo-3-methylbenzoic acid are added and the mixture is degassed with argon for 10 minutes. Pd (PPh ₃ ) ₄ (175 mg, 0.15 mmol) is then added and the reaction medium is refluxed and stirred for 24 hours. The reaction medium is then treated with saturated ammonium chloride solution and then extracted with ethyl acetate. The combined organic phases are dried and then concentrated under reduced pressure. The residue is then dissolved in 50 mL of methanol, 1 mL of sulfuric acid is added and then refluxed for 18 h. After cooling, treatment with water and the mixture is extracted with ethyl acetate. The combined organic phases are dried and concentrated under reduced pressure. The residue is then purified by chromatography on silica column. Colorless oil is obtained (m = 180 mg, Y = 15%).
[281] f) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylsulfanylmethyl] -2-hydroxymethylphenyl} methanol
[282] 130 mg (0.3 mmol) of methyl 3 '-[3,4-bis (hydroxymethyl-benzylsulfanyl) -2-methylbiphenyl-4-carboxylate are dissolved in 10 mL of dry THF, followed by ethylmagnesium bromide 0.7 mL (2 mmol) of solution (3M) are added. The reaction medium is stirred for 1 hour and then treated with ammonium chloride solution. After extraction with ethyl acetate, the organic phases are combined, dried and concentrated under reduced pressure. The residue is purified by chromatography on a silica column. Colorless oil is obtained (m = 105 mg; Y = 81%).
[283]
[284] Example 11
[285] {4- [4 '(1-ethyl-1-hydroxypropyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[286] a) 3-bromo-2-methylphenol
[287] 20 g (107 mmol) of 3-bromo-2-methylphenylamine are dissolved in 150 mL of aqueous 1.0 M sulfuric acid and the mixture is cooled to 0 ° C. A solution of 8.9 g (129 mmol) of sodium nitrite in 20 mL of water is slowly added dropwise. The medium is stirred at 0 ° C. for 15 minutes and then 50 mL of concentrated sulfuric acid is added. The reaction medium is then heated to 100 ° C. for 1 hour, then cooled and diluted with water. After extraction with ethyl ether, the obtained residue is recrystallized from a heptane / dichloromethane mixture. A yellow solid is obtained (m. P. = 89 ° C; m = 12.3 g; Y = 61%).
[288] b) 1-bromo-3-methoxymethoxy-2-methylbenzene
[289] 13.9 g (74 mmol) of 3-bromo-2-methylphenol are dissolved in 120 mL of dimethylformamide and the mixture is cooled to 0 ° C. 3.6 g (90 mmol) of 60% sodium hydride are then added in portions and the medium is stirred for 1 hour. 6.8 mL (90 mmol) of methoxymethyl chloride are then slowly added and the medium is allowed to warm to room temperature and stirred for 1 hour. After routine treatment, the residue is purified by chromatography on silica gel (eluent: 80 heptanes / 20 ethyl acetate). The desired product is obtained in the form of a colorless oil (m = 16.2 g; Y = 95%).
[290] c) 3-methoxymethoxy-2-methylbenzene-1-boric acid
[291] 16.2 g (70 mmol) of 1-bromo-3-methoxymethoxy-2-methylbenzene are dissolved in 200 mL of anhydrous THF and the mixture is cooled to -78 ° C. 33.7 mL (84 mmol) of 2.5M butyllithium is added slowly and then the mixture is kept at -78 ° C for 1 hour. 19.4 mL (84 mmol) of triisopropyl borate are then added dropwise over 15 minutes. The medium is stirred at the same temperature for 30 minutes and then poured into 300 mL of 1N hydrochloric acid. After routine treatment, the pale white solid residue obtained is rinsed with heptane and then dried under reduced pressure. A flaky white solid is obtained (m = 11.8 g; Y = 86%).
[292] d) methyl 3'-hydroxy-2,2'-dimethylbiphenyl-4-carboxylate
[293] 1.03 g (5.2 mmol) of 3-methoxymethoxy-2-methylbenzene-1-boric acid, 1 g (4.4 mmol) of methyl 4-bromo-3-methylbenzoate and 4.4 mL of 2.0 M potassium carbonate solution were added to ethylene glycol Dissolve in 20 mL of dimethyl ether. The mixture is degassed for 10 minutes using a nitrogen stream, then 250 mg (0.22 mmol) of tetrakis (triphenylphosphine) palladium are added and the medium is stirred at 80 ° C. for 24 hours. After cooling and routine treatment, the obtained residue is dissolved in 30 mL of methanol and 0.5 mL of sulfuric acid is added. The medium is stirred for 6 hours at room temperature and then poured into an ethyl ether / water mixture. After extraction with ether, the residue is purified by chromatography on silica gel (eluent: 9 heptane / 1 ethyl acetate). The desired product is obtained in the form of a dark colorless oil (m = 890 mg; Y = 79%).
[294] e) methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,2'-dimethylbiphenyl-4-carboxylate
[295] In a similar manner as in Example 1 (i), 515 mg (2 mmol) of methyl 3'-hydroxy-2,2'-dimethylbiphenyl-4-carboxylate were added to 3,4-bis (benzoyloxymethyl) Reaction with 880 mg (2 mmol) of benzyl bromide and 300 mg (2.2 mmol) of potassium carbonate give the desired product in the form of a colorless oil (m = 1.22 g; Y = 99%).
[296] f) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[297] In a manner similar to that in Example 1 (j), methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,2'-dimethylbiphenyl-4-carboxylate 1.22 g (1.98 mmol) is reacted with 5.3 mL (16 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 81-82 ° C .; m = 360 mg; Y = 42%).
[298]
[299] Example 12
[300] {2-hydroxymethyl-4- [4 '-(1-hydroxy-1-propylbutyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] phenyl} methanol
[301] a) {2-hydroxymethyl-4- [4 '-(1-hydroxy-1-propylbutyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] phenyl} methanol
[302] In a similar manner as in Example 1 (j), methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,2'-dimethylbiphenyl-4-carboxylate ( 100 mg (0.25 mmol) are reacted with 0.5 mL (1 mmol) of 2.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 118-120 ° C.). m = 64 mg; Y = 56%).
[303]
[304] Example 13
[305] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[306] a) methyl 3'-hydroxy-2'-methylbiphenyl-4-carboxylate
[307] In a manner similar to that of Example 11 (d), 3.3 g (16.7 mmol) of 3-methoxymethoxy-2-methylbenzene-1-boric acid (described in Example 11 (c)) was added ethyl 4-iodo. Reaction with 3 g (13.9 mmol) of benzoate, 16.7 mL of 2.0 M potassium carbonate solution and 800 mg (0.69 mmol) of tetrakis (triphenylphosphine) palladium, followed by deprotection in methanol, the desired product in the form of a colorless oil. Obtained (m = 3.07 g; Y = 77%).
[308] b) methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2'-methylbiphenyl-4-carboxylate
[309] In a similar manner as in Example 1 (i), 1 g (4.1 mmol) of methyl 3'-hydroxy-2'-methylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl bromide Reaction with 2 g (4.5 mmol) and 650 mg (4.7 mmol) potassium carbonate gives the desired product in the form of a colorless oil (m = 2.4 g; Y = 97%)
[310] c) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[311] In a similar manner as in Example 1 (j), 2.4 g of methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2'-methylbiphenyl-4-carboxylate ( 4 mmol) is reacted with 10.7 mL (32 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 117-118 ° C .; m = 1.1 mg; Y = 60%).
[312]
[313] Example 14
[314] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[315] a) methyl 3'-hydroxy-2,6,2'-trimethylbiphenyl-4-carboxylate
[316] In a similar manner as in Example 11 (d), 1.5 g (7.6 mmol) of 3-methoxymethoxy-2-methylbenzene-1-boric acid (described in Example 11 (c)) was added to methyl 3,5- 2 g (6.4 mmol) of dimethyl-4-trifluoromethanesulfonyloxybenzoate, 7.7 mL of 2.0 M potassium carbonate solution, and 370 mg (0.32 mmol) of tetrakis (triphenylphosphine) palladium followed by descalation in methanol Gelatinization gives the desired product in the form of a white solid (mp = 149 ° C; m = 1.34 g; Y = 67%).
[317] b) methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,6,2'-trimethylbiphenyl-4-carboxylate
[318] In a similar manner as in Example 1 (i), 980 mg (3.6 mmol) of methyl 3'-hydroxy-2,6,2'-trimethylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxy React with 1.75 g (4.5 mmol) of methyl) benzyl bromide and 570 mg (4.1 mmol) of potassium carbonate to afford the desired product in the form of white crystals (mp = 131-132 ° C .; m = 2.16 g; Y = 95% )
[319] c) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[320] In a manner similar to that of Example 1 (j), methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,6,2'-trimethylbiphenyl-4-carboxyl React 2.1 g (3.3 mmol) of the rate with 8.9 mL (27 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 105-107 ° C .; m = 1.1 mg; Y = 73% ).
[321]
[322] Example 15
[323] (4- {3- [5- (1-ethyl-1-hydroxypropyl) -2-pyridyl] phenoxymethyl} -2-hydroxymethylphenyl} methanol
[324] a) ethyl 6- (3-hydroxybiphenyl) nicotinate
[325] In a similar manner as in Example 1 (h), 1 g (6.7 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) and 1.5 g (5.6 mmol) of ethyl 6-iodonicotinate ) Is reacted with 5.6 mL of 2 M potassium carbonate and 320 mg of tetrakis (triphenylphosphine) palladium and then deprotected in ethanol to give the desired product in the form of a white solid (m = 354 mg; Y = 26%). ).
[326] b) ethyl 6- {3- [3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] phenyl} nicotinate
[327] In a similar manner as in Example 1 (i), 277 mg (1.1 mmol) of ethyl 6- (3-hydroxyphenyl) nicotinate was added 500 mg (1.1 mmol) of 3,4-bis (benzoyloxymethyl) benzyl bromide And 166 mg (1.2 mmol) of potassium carbonate. The desired product is obtained in the form of white crystals (m. P. = 118-120 ° C; m = 500 mg; Y = 73%).
[328] c) (4- {3- [5- (1-ethyl-1-hydroxypropyl) -2-pyridyl] phenoxymethyl} -2-hydroxymethylphenyl} methanol
[329] In a similar manner as in Example 1 (j), 410 mg (0.68 mmol) of ethyl 6- {3- [3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] phenyl} nicotinate was added to 3.0M. Reaction with 1.8 mL (5.4 mmol) of ethylmagnesium bromide yields the desired product in the form of a colorless paste (m = 143 mg; Y = 51%).
[330]
[331] Example 16
[332] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[333] a) 3-bromo-4-methylphenol
[334] In a similar manner as in Example 11 (a), 20 g (107 mmol) of 3-bromo-4-methylphenylamine are reacted with 8.9 g (129 mmol) of sodium nitrite to give a brown oil without purification (m = 20 g; Y = 100%).
[335] b) 2-bromo-4-methoxymethoxy-1-methylbenzene
[336] In a similar manner as in Example 11 (b), 20 g (107 mmol) of 3-bromo-4-methylphenol was added with 5.6 g (139 mmol) of 60% sodium hydride and 8.9 mL (139 mmol) of methoxymethyl chloride. By reaction, the desired product is obtained in the form of an orange oil (m = 12.3 g; Y = 50%).
[337] c) 4-methoxymethoxy-1-methylbenzene-2-boric acid
[338] In a similar manner as in Example 11 (c), 12.3 g (53 mmol) of 2-bromo-4-methoxymethoxy-1-methylbenzene was added 28 mL (69 mmol) of 2.5M butyllithium and triisopropyl borate. Reaction with 18.4 mL (80 mmol) gives a brown oil (m = 10.4 g; Y = 99%).
[339] d) methyl 5'-hydroxy-2,2'-dimethylbiphenyl-4-carboxylate
[340] In a similar manner as in Example 11 (d), 3.7 g (18.8 mmol) of 4-methoxymethoxy-1-methylbenzene-2-boric acid was added to 3.9 g (17 mmol of methyl 4-bromo-3-methylbenzoate. ), 17 mL of 2.0 M potassium carbonate solution and 1 mg (0.85 mmol) of tetrakis (triphenylphosphine) palladium, followed by deprotection in methanol to give the desired product in the form of a dark colorless oil (m = 2.87). mg; Y = 51%).
[341] e) methyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,2'-dimethylbiphenyl-4-carboxylate
[342] In a similar manner as in Example 1 (i), 2.24 g (8.7 mmol) of methyl 5'-hydroxy-2,2'-dimethylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) Reaction with 4.20 mg (9.6 mmol) of benzyl bromide and 1.26 g (9 mmol) of potassium carbonate give the desired product in the form of a colorless oil (m = 5.34 g; Y = 99%)
[343] f) {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[344] Methyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,2'-dimethylbiphenyl-4-carboxylate 5.3 in a similar manner as in Example 1 (j) g (8.6 mmol) is reacted with 23 mL (69 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (m = 1.68 g; Y = 45%).
[345]
[346] Example 17
[347] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[348] a) methyl 5'-hydroxy-2,6,2'-trimethylbiphenyl-4-carboxylate
[349] In a similar manner as in Example 11 (d), 3.7 g (18.8 mmol) of 4-methoxymethoxy-1-methylbenzene-2-boric acid (described in Example 16 (c)) was added to methyl 3,5-. After reaction with 5.3 g (17 mmol) of dimethyl-4-trifluoromethanesulfonyloxybenzoate, 17 mL of 2.0 M potassium carbonate solution and 1 g (0.82 mmol) of tetrakis (triphenylphosphine) palladium, it was deboled in methanol. Gelatinization gives the desired product in the form of a yellow oil (m = 3.0 g; Y = 65%).
[350] b) methyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,6,2'-trimethylbiphenyl-4-carboxylate
[351] In a similar manner as in Example 1 (i), 1.53 g (5.6 mmol) of methyl 5'-hydroxy-2,6,2'-trimethylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxy React with 2.73 g (6.2 mmol) of methyl) benzyl bromide and 980 mg (5.8 mmol) of potassium carbonate to afford the desired product in the form of a yellow oil (m = 3.5 g; Y = 98%)
[352] c) {4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[353] In a similar manner as in Example 1 (j), methyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,6,2'-trimethylbiphenyl-4-carboxyl 3.5 g (5.8 mmol) of the rate are reacted with 15.3 mL (46 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 128 ° C .; m = 1.45 g; Y = 56%).
[354]
[355] Example 18
[356] {4- [4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[357] a) ethyl 5'-hydroxy-2'-methylbiphenyl-4-carboxylate
[358] In a manner similar to that of Example 11 (d), 3.7 g (18.8 mmol) of 4-methoxymethoxy-1-methylbenzene-2-boric acid described in Example 16 (c) was added to ethyl 4-iodobenzoate 4.7. g (17 mmol), 17 mL of 2.0 M potassium carbonate solution and 1 g (0.8 mmol) of tetrakis (triphenylphosphine) palladium, followed by deprotection in ethanol to give the desired product in the form of a colorless oil ( m = 3.07 g; Y = 71%).
[359] b) ethyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2'-methylbiphenyl-4-carboxylate
[360] In a similar manner as in Example 1 (i), 3.07 g (12 mmol) of ethyl 5'-hydroxy-2'-methylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl bromide Reaction with 6.7 g (15 mmol) and 2 mg (14 mmol) of potassium carbonate give the desired product in the form of a colorless oil (m = 5.7 g; Y = 77%)
[361] c) {4- [4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[362] In a similar manner as in Example 1 (j), 3.8 g of ethyl 5 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2'-methylbiphenyl-4-carboxylate ( 6.2 mmol) is reacted with 16.7 mL (50 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (m = 1.26 mg; Y = 48%).
[363]
[364] Example 19
[365] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2', 6'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[366] (a) Methyl 3'-hydroxy-2,6-dimethylbiphenyl-4-carboxylate
[367] In a manner similar to that of Example 1 (h), 4.48 g (24 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) was added to methyl 3,5-dimethyl-4-trifluoro. Reaction with 7 g (22.4 mmol) methanesulfonyloxybenzoate, 24 mL 2M potassium carbonate and 1.29 g (1.1 mmol) tetrakis (triphenylphosphine) palladium followed by deprotection in methanol affords the desired product.
[368] (b) methyl 3 '-[3,4-bis (1-phenylmethanyloxymethyl) benzyloxy] -2,6-dimethylbiphenyl-4-carboxylate
[369] In a manner similar to that of Example 1 (i), 4.49 g (17.5 mmol) of methyl 3'-hydroxy-2,6-dimethylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl Reaction with 8.46 g (19 mmol) bromide and 2.54 g (18 mmol) potassium carbonate give the desired product in the form of a yellow oil (m = 7.4 g; Y = 69%).
[370] (c) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2', 6'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[371] 5.4 g of methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2,6-dimethylbiphenyl-4-carboxylate in a similar manner as in Example 1 (j) (8.8 mmol) is reacted with 23.3 mL (70 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 133 ° C .; m = 2.4 g; Y = 65%).
[372]
[373] Example 20
[374] 1- {4- [3- (3,4-bis-hydroxymethylbenzyloxy) phenyl] -2-thiophenyl} -1-propanol
[375] a) 1- (4-bromo-2-thiophenyl) -1-propanol
[376] 10 g (52 mmol) of 4-bromothiophene-2-carbaldehyde are dissolved in 200 mL of ethyl ether and 20 mL of THF. 26.6 mL (78 mmol) of 3.0M ethylmagnesium bromide are added slowly. After 2 hours at room temperature, the reaction medium is poured into saturated ammonium chloride solution. After extraction, a yellow oil is obtained (m = 11.5 g, Y = 99%).
[377] b) 1- (4-bromo-2-thiophenyl) -1-propanone
[378] 11.5 g (52 mmol) of 1- (4-bromo-2-thiophenyl) -1-propanol are dissolved in 300 mL of dichloromethane. 60 g (690 mmol) of manganese dioxide are added and the reaction medium is stirred for 14 hours and then filtered. The desired product is obtained in the form of an orange oil (m = 11.4 g, Y = 99%)
[379] c) 1- [4- (3-hydroxyphenyl) -2-thiophenyl] -1-propanone
[380] In a manner similar to that of Example 1 (h), 4.6 g (25 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) and 1- (4-bromo-2-thiophenyl 5 g (22.8 mmol) of 1--1-propanone were reacted with 22.8 mL of 2.0 M potassium carbonate and 1.32 g of tetrakis (triphenylphosphine) palladium, followed by deprotection in methanol to afford the desired product as a white solid. (Mp = 112 ° C .; m = 3.87 g; Y = 73%)
[381] d) 1- {4- [3- (3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy) phenyl] -2-thiophenyl} -1-propanone
[382] In a similar manner as in Example 1 (i), 3.8 g (16.3 mmol) of 1- [4- (3-hydroxyphenyl) -2-thiophenyl] -1-propanone were added to 3,4-bis (benzoyloxy). Reaction with 16.9 g (18 mmol) of methyl) benzyl bromide and 2.36 g (17 mmol) of potassium carbonate give the desired product in the form of white crystals (mp = 117 ° C .; m = 9.1 g; Y = 95%).
[383] e) 1- {4- [3- (3,4-bis-hydroxymethylbenzyloxy) phenyl] -2-thiophenyl} -1-propanol
[384] 4.3 g (7.3 mmol) of 1- {4- [3- (3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy) phenyl] -2-thiophenyl} -1-propanone in 10 mL THF It is dissolved and added dropwise to a suspension of 1.1 g (29 mmol) of lithium aluminum hydride, and the mixture is stirred for 2 hours. Treat the reaction medium with 1.1 mL of water, 1.1 mL of 15% sodium hydroxide and 3.3 mL of water, then filter the medium. After purification by chromatography on silica gel (eluent: 3 heptanes / 7 ethyl acetate), the desired product is obtained in the form of a colorless oil (m = 773 mg; Y = 28%).
[385]
[386] Example 21
[387] (4- {3- [4- (1-ethyl-1-hydroxypropyl) -2-thiophenyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
[388] (a) (4- {3- [4- (1-ethyl-1-hydroxypropyl) -2-thiophenyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
[389] In a similar manner as in Example 1 (j), 1- {4- [3- (3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy) phenyl] -2-thiophenyl} -1-propane 4.3 g (7.3 mmol) of warm (described in Example 20 (d)) are reacted with 17 mL (51 mmol) of 3.0 M ethylmagnesium bromide to give the desired product in the form of a white solid (mp = 47 ° C .; m = 1.54 g; Y = 51%).
[390]
[391] Example 22
[392] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy] -2-hydroxymethylphenyl} methanol
[393] (a) 1- (4-bromo-3-methylphenyl) -1-propanone
[394] After 25 g (116 mmol) of 4-bromo-3-methylbenzoic acid are dissolved in 250 mL of dichloromethane, the mixture is cooled to 0 ° C. 10.1 mL (116 mmol) of oxalyl chloride is added slowly, followed by several drops of dimethylformamide and 16 mL (116 mmol) of triethylamine. After 30 minutes, 12.5 g (128 mmol) of N, O-dimethylhydroxylamine hydrochloride are slowly added, followed by 35.5 mL (255 mmol) of triethylamine. The medium is stirred for 14 hours, then treated with ammonium chloride solution and extracted with dichloromethane. The crude residue is then taken up in ethyl ether, rinsed with 1N sodium hydroxide solution, dried and concentrated. The obtained intermediate amide is dissolved in 300 mL of dry THF and cooled to -78 ° C. 40 mL (120 mmol) of 3.0M ethylmagnesium bromide are slowly added to raise the reaction medium to 0 ° C. and then stirred for 18 hours. After routine treatment and chromatography on silica gel (9 heptanes / 1 ethyl acetate), the desired product is obtained in the form of a dark colorless oil (m = 17 g, Y = 64%).
[395] b) 2- (4-bromo-3-methylphenyl) -2-ethyl- [1,3] dioxolane
[396] 16 g (70 mmol) of 1- (4-bromo-3-methylphenyl) -1-propanone are dissolved in 200 mL of toluene. 20 mL (350 mmol) of ethylene glycol and 670 mg (3.5 mmol) of para-toluenesulfonic acid are added. The blend is mounted in a Dean-Stark distillation apparatus and the reaction medium is heated at 130 ° C. for 16 hours. After cooling the medium, it is poured into sodium bicarbonate solution and extracted with ethyl ether. The crude product obtained is in the form of a colorless oil (m = 18.6 g, Y = 98%)
[397] c) 4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-carbaldehyde
[398] In a manner similar to that of Example 1 (h), 6.6 g (44 mmol) of 3-formylbenzeneboric acid and 2- (4-bromo-3-methylphenyl) -2-ethyl- [1,3] dioxolane 10 g (37 mmol) is reacted with 45 mL of 2.0 M potassium carbonate and 2.14 g of tetrakis (triphenylphosphine) palladium to afford the desired product in the form of a thick oil (m = 9.1 g; Y = 84%).
[399] d) [4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-yl] methanol
[400] In a similar manner as in Example 20 (e), 4.5 g (15.2 mmol) of 4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-carbaldehyde ) Is reacted with 760 mg (20 mmol) of lithium aluminum hydride to give the desired product in the form of a colorless oil (m = 4.4 g, Y = 97%).
[401] e) dimethyl 4- [4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-ylmethoxy] phthalate
[402] 4.4 g (14 mmol) of [4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-yl] methanol are dissolved in 120 mL of dichloromethane and the mixture is Is cooled to 0 ° C. 2.93 mL (16.8 mmol) of diisopropylethylamine is added, followed by the slow addition of 1.14 mL (14.7 mmol) of methanesulfonyl chloride. After stirring for 30 minutes, the reaction medium is poured into ammonium chloride solution. After routine treatment, the obtained residue is dissolved in 150 mL of 2-butanone. 4.2 g (28 mmol) of sodium iodide, 2.13 g (15.4 mmol) of potassium carbonate and 3.23 g (15.4 mmol) of dimethyl 4-hydroxyphthalate are continuously added to the solution. The reaction medium is heated to 85 ° C. for 18 h and then filtered and concentrated. The obtained residue is purified by chromatography on silica gel (eluent: 8 heptane / 2 ethyl acetate). The desired product is obtained in the form of a colorless oil (m = 6.89 g, Y = 100%).
[403] f) dimethyl 4- (2'-methyl-4'-propionylbiphenyl-3-ylmethoxy) phthalate
[404] 6.8 g (14 mmol) of dimethyl 4- [4 '-(2-ethyl- [1,3] dioxolan-2-yl) -2'-methylbiphenyl-3-ylmethoxy] phthalate were dissolved in 200 mL of methanol and water. Dissolve in 50 mL. 0.5 mL of sulfuric acid is added and the reaction medium is stirred at room temperature for 10 hours. After routine treatment, the desired product is obtained without purification, in the form of a colorless oil (m = 6.05 g, Y = 97%).
[405] g) dimethyl 4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy) phthalate
[406] 5 g (11.2 mmol) of dimethyl 4- (2'-methyl-4'-propionylbiphenyl-3-ylmethoxy) phthalate are dissolved in 15 mL of dichloromethane and the mixture is cooled to 0 ° C. 1.42 mL (11.2 mmol) of trimethylsilyl chloride are added, followed by 13.4 mL (13.4 mmol) of 1.0 M dimethylzinc. The medium is stirred for 6 hours and then treated with 10 mL of methanol. 20 mL of 1N hydrochloric acid solution is added and stirring is continued for 1 hour. After extraction with dichloromethane and purification by column on silica gel (eluent: 6 heptane / 4 ethyl acetate), the desired product is obtained in the form of a colorless oil (m = 3.25 g, Y = 61%).
[407] h) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy] -2-hydroxymethylphenyl} methanol
[408] In a similar manner as in Example 20 (e), 1.5 g (3.15 mmol) of dimethyl 4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy) phthalate Is reacted with 480 mg (12.6 mmol) of lithium aluminum hydride to give the desired product in the form of a white solid (mp = 87 ° C .; m = 1.03 g, Y = 78%).
[409]
[410] Example 23
[411] 1- [3 '-(3,4-bis-hydroxymethylphenoxymethyl) -2-methylbiphenyl-4-yl] -1-propanol
[412] a) 1- [3 '-(3,4-bis-hydroxymethylphenoxymethyl) -2-methylbiphenyl-4-yl] -1-propanol
[413] 900 mg (2) in dimethyl 4- (2'-methyl-4'-propionylbiphenyl-3-ylmethoxy) phthalate (as described in Example 22 (f)) in a similar manner as in Example 20 (e) mmol) is reacted with 300 mg (8 mmol) of lithium aluminum hydride to give the desired product in the form of a white solid (mp = 78 ° C .; m = 737 mg, Y = 94%).
[414]
[415] Example 24
[416] {5- [4 '-(1-ethyl-1-hydroxypropyl) -3'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[417] (a) Methyl 3'-hydroxy-3-methylbiphenyl-4-carboxylate
[418] In a similar manner as in Example 1 (h), 5.35 g (29 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) and 5.7 g of 4-bromo-2-methylbenzoic acid ( 26.7 mmol) is reacted with 26.7 mL of 2.0 M potassium carbonate and 1.54 g of tetrakis (triphenylphosphine) palladium and then deprotected in methanol to give the desired product in the form of a colorless oil (m = 3.22 g; Y = 50%).
[419] b) methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -3-methylbiphenyl-4-carboxylate
[420] In a similar manner as in Example 1 (i), 1.5 g (6.2 mmol) of methyl 3'-hydroxy-3-methylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl bromide 3 Reaction with g (6.88 mmol) and 900 mg (6.4 mmol) potassium carbonate gives the desired product in the form of a yellow oil (m = 3.69 g; Y = 99%).
[421] c) {5- [4 '-(1-ethyl-1-hydroxypropyl) -3'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[422] In a similar manner as in Example 1 (j), 4.6 g (7.6 g) of methyl 3 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -3-methylbiphenyl-4-carboxylate (7.6) mmol) is reacted with 30.6 mL (61 mmol) of 2.0 M ethylmagnesium chloride to afford the desired product in the form of a white solid (mp = 76 ° C .; m = 1.32 g; Y = 42%).
[423]
[424] Example 25
[425] {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-4-yloxymethyl] -2-hydroxymethylphenyl} methanol
[426] a) 4-methoxymethoxyphenylboric acid
[427] In a similar manner as in Example 1 (g), 10 g (57.8 mmol) of 4-bromophenol was reacted with 2.55 g (63.6 mmol) of 60% sodium hydride and 4.83 mL (63.6 mmol) of methoxymethyl chloride, Reaction with 25.4 mL (63.6 mmol) of 2.5M butyllithium solution and 15 mL (65 mmol) of triisopropyl borate yields a brown solid (mp = 65 ° C .; m = 6.2 g; Y = 7.3%).
[428] b) methyl 4'-hydroxy-2-methylbiphenyl-4-carboxylate
[429] In a similar manner as in Example 1 (h), 1.61 g (8.7 mmol) of 4-methoxymethoxyphenylboric acid and 1.8 g (9.7 mmol) of 4-bromo-3-methylbenzoic acid were added to 26.7 mL of 2.0 M potassium carbonate and After reaction with 1.54 g of tetrakis (triphenylphosphine) palladium followed by deprotection-esterification in methanol, the desired product is obtained in the form of a colorless oil (m = 2.06 g; Y = 98%).
[430] c) methyl 4 '-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate
[431] In a similar manner as in Example 1 (i), 2.0 g (8.7 mmol) of methyl 4'-hydroxy-2-methylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl bromide 4.3 Reaction with g (9.8 mmol) and 1.29 g (9.3 mmol) of potassium carbonate give the desired product in the form of a yellow oil (m = 4.88 g; Y = 91%).
[432] d) {4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-4-yloxymethyl] -2-hydroxymethylphenyl} methanol
[433] In a manner similar to that of Example 1 (j), 4.9 g of methyl 4 ′-[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2-methylbiphenyl-4-carboxylate (8 mmol) is reacted with 35 mL (70 mmol) of 2.0 M ethylmagnesium chloride to afford the desired product in the form of a white solid (mp = 97 ° C .; m = 426 mg; Y = 13%).
[434]
[435] Example 26
[436] {4- [2'-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[437] a) ethyl 3'-hydroxy-2-tert-butylbiphenyl-4-carboxylate
[438] In a manner similar to that of Example 1 (h), 6.8 g (37 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) was added ethyl 3-tert-butyl-4-trifluoro Reaction with 11 g (31 mmol) of methanesulfonyloxybenzoate, 37 mL of 2.0 M potassium carbonate and 1.8 g of tetrakis (triphenylphosphine) palladium followed by deprotection in ethanol to give the desired product in the form of pink crystals. (Mp = 118-120 ° C .; m = 5.3 g; Y = 57%).
[439] b) ethyl 3 '[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2-tert-butylbiphenyl-4-carboxylate
[440] In a manner similar to that of Example 1 (i), 5.3 g (17.7 mmol) of methyl 3'-hydroxy-2-tert-butylbiphenyl-4-carboxylate was added to 3,4-bis (benzoyloxymethyl) benzyl Reaction with 8.46 g (19 mmol) of bromide and 2.54 g (18 mmol) of potassium carbonate give the desired product in the form of a yellow oil (m = 11 g; Y = 94%).
[441] c) {4- [4 '(1-ethyl-1-hydroxypropyl) -2'-tert-butylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
[442] In a similar manner as in Example 1 (j), 3 g of methyl 3 '[3,4-bis (1-phenylmethanoyloxymethyl) benzyloxy] -2-tert-butylbiphenyl-4-carboxylate ( 4.6 mmol) is reacted with 12 mL (36 mmol) of 3.0M ethylmagnesium bromide to give the desired product in the form of a white powder (mp = 133 ° C .; m = 1.7 g; Y = 80%).
[443]
[444] Example 27
[445] 1- [3 '-(3,4-bis-hydroxymethylbenzyloxy) -2-methylbiphenyl-4-yl] -2,2-dimethyl-1-propanol
[446] a) 4'-bromo-2'-methylbiphenyl-3-ol
[447] In a similar manner as in Example 1 (h), 15.3 g (84 mmol) of 3-methoxymethoxyphenylboric acid (described in Example 1 (g)) and 25 g of 2-bromo-5-iodotoluene (84 mmol) is reacted with 84 mL of 2.0 M potassium carbonate and 4.8 g of tetrakis (triphenylphosphine) palladium and then deprotected in methanol to give the desired product in the form of a colorless oil (m = 11.8 g; Y = 50%).
[448] b) dimethyl 4-bromomethylphthalate
[449] 36 g (176 mmol) of dimethyl 4-hydroxymethyl-phthalate are dissolved in 300 mL of dichloromethane and 70 g (211 mmol) of tetrabromomethane are added. Then a solution of 55.3 g (211 mmol) of triphenylphosphine in 200 mL of dichloromethane is added slowly, then the reaction mixture is stirred at room temperature for 3 hours. After treatment with water and extraction with dichloromethane, the residue is purified by chromatography on a silica column (eluent: dichloromethane). The desired product is obtained in the form of a colorless oil (m = 25 g; Y = 50%).
[450] c) dimethyl 4-4'-bromo-2'-methylbiphenyl-3-yloxymethyl) phthalate
[451] In a similar manner as in Example 1 (i), 11.8 g (44.8 mmol) of 4'-bromo-2'-methylbiphenyl-3-ol was added to 14.2 g (49 mmol) of dimethyl 4-bromomethylphthalate and carbonic acid. Reaction with 6.5 g (47 mmol) of potassium gives the desired product in the form of a yellow oil (m = 16.4 g; Y = 78%).
[452] d) [4 '-(4'-bromo-2'-methylbiphenyl-3-yloxymethyl) -2-hydroxymethylphenyl] methanol
[453] 16.4 g (35 mmol) of dimethyl 4-4'-bromo-2'-methylbiphenyl-3-yloxymethyl) phthalate are dissolved in 200 mL of dry THF, and 1.5 g (70 mmol) of lithium borohydride are added. do. The reaction medium is refluxed for 3 hours, then cooled and poured onto ice, then diluted with saturated ammonium chloride solution. After extraction, the desired product is obtained in the form of a colorless oil (m = 13.3 g, Y = 100%).
[454] e) 3 '-(3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -4-bromo-2-methylbiphenyl
[455] 13.3 g (34.8 mmol) of [4 '-(4'-bromo-2'-methylbiphenyl-3-yloxymethyl) -2-hydroxymethylphenyl] methanol are dissolved in 100 mL of anhydrous DMF. 11.5 g (76 mmol) of tert-butyldimethylchlorosilane and then 6.6 g (97 mmol) of imidazole are added. The medium is stirred for 10 hours and then diluted with 400 mL of ethyl ether and filtered. The filtrate is then treated with saturated ammonium chloride solution and rinsed with water. After chromatography on a silica gel column, the desired product is obtained in the form of a colorless oil (m = 20.4 g; Y = 91%).
[456] f) 1- {3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl} -2,2-dimethyl-1-propanol
[457] 2 g (3 mmol) of 3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -4-bromo-2-methylbiphenyl are dissolved in 30 mL of anhydrous THF and the mixture Cool to -78 ° C. 1.4 mL (3.5 mmol) of 2.5M butyllithium are slowly added and the mixture is kept at -78 ° C for 1 hour. 400 mL (3.7 mmol) of 2,2-dimethylpropionaldehyde is added dropwise and the medium is slowly warmed to room temperature and treated according to routine treatment. The desired product is obtained in the form of a colorless oil (m = 2 g; Y = 100%).
[458] g) 1- [3 '-(3,4-bis-hydroxymethylbenzyloxy) -2-methylbiphenyl-4-yl] -2,2-dimethyl-1-propanol
[459] 2 g of 1- {3 '-(3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl} -2,2-dimethyl-1-propanol ( 3 mmol) is dissolved in 20 mL of THF, and 7.7 mL (7.7 mmol) of 1M tetrabutylammonium fluoride are added dropwise, after stirring at room temperature for 1 hour, and then routinely treated, the obtained residue is chromatographed on silica gel. Purification by chromatography The desired product is obtained in the form of a colorless oil (m = 1.15 g; Y = 90%).
[460]
[461] Example 28
[462] 1- [3 '-(3,4-bis-hydroxymethylbenzyloxy) -2-methylbiphenyl-4-yl] -2-methyl-1-propanol
[463] a) 1- {3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl} -2-methyl-1-propanol
[464] In a similar manner as in Example 27 (f), 2 g of 3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -4-bromo-2-methylbiphenyl (3.1 mmol) is reacted with 1.4 mL (3.5 mmol) of 2.5 M butyllithium and 400 μl (37 mmol) of 2-methylpropionaldehyde to give the desired product in the form of a colorless oil (m = 1.1 g; Y = 56%). .
[465] b) 1- [3 '-(3,4-bis-hydroxymethylbenzyloxy) -2-methylbiphenyl-4-yl] -2-methyl-1-propanol
[466] In a similar manner as in Example 27 (g), 1- {3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl}- 1.1 g (1.7 mmol) of 2-methyl-1-propanol was reacted with 3.8 mL (3.8 mmol) of 1.0 M tetrabutylammonium fluoride to afford the desired product in the form of a colorless oil (m = 460 mg; Y = 65). %).
[467]
[468] Example 29
[469] {2-hydroxymethyl-4- [methyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[470] a) 2- {3 '-(3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl} -1,1,1,3,3, 3-hexafluoro-2-propanol
[471] In a similar manner as in Example 27 (f), 4 g of 3 '-[3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -4-bromo-2-methylbiphenyl (6.2 mmol) is reacted with 2.7 mL (6.8 mmol) of 2.5M butyllithium and excess hexafluoroacetone to give the desired product in the form of a colorless oil (m = 2.35 g; Y = 52%).
[472] b) {2-hydroxymethyl-4- [methyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[473] In a similar manner as in Example 27 (g), 2- {3 '-(3,4-bis- (tert-butyldimethylsilanyloxymethyl) benzyloxy] -2-methylbiphenyl-4-yl}- 2.3 g (3.2 mmol) of 1,1,1,3,3,3-hexafluoro-2-propanol were reacted with 7 mL (7 mmol) of 1.0 M tetrabutylammonium fluoride to give the desired product in the form of a colorless oil. (M = 1.2 g; Y = 75%).
[474]
[475] Example 30: Formulation example
[476] 1) Oral route
[477] (a) The following composition is prepared in the form of 0.2 g tablets:
[478] 0.005 g of the compound of Example 1
[479] Pregelatinized starch 0.065 g
[480] Microcrystalline Cellulose0.075 g
[481] Lactose0.050 g
[482] Magnesium Stearate0.005 g
[483] For treating young children, one to three tablets per day are administered to an adult individual for one to twelve months depending on the severity of the condition to be treated.
[484] (b) Prepare a drinkable suspension to be packaged in a 5 ml ampoule:
[485] Compound of Example 2 0.005 mg
[486] Glycerol0.500 g
[487] 70% Sorbitol0.500 g
[488] Sodium Saccharate0.010 g
[489] Methyl para-hydroxybenzoate0.040 g
[490] Spice
[491] 5 ml of purified water
[492] For acne treatment, one ampoule per day is administered to an adult individual for 1 to 12 months, depending on the severity of the condition to be treated.
[493] (c) Prepare the following formulation to be packaged in gel capsules:
[494] Compound of Example 4 0.0001 mg
[495] Corn starch0.060 g
[496] Lactose Proper 0.300 g
[497] Gel capsules used consist of gelatin, titanium oxide and preservatives.
[498] In the treatment of psoriasis, one gel capsule per day is administered to an adult individual for 1 to 12 months.
[499] (d) Prepare the following formulation to be packaged in gel capsules:
[500] Compound of Example 5 0.02 mg
[501] Cyclosporine0.050 g
[502] Corn starch0.060 g
[503] Lactose Proper 0.300 g
[504] Gel capsules used consist of gelatin, titanium oxide and preservatives.
[505] In the treatment of psoriasis, one gel capsule per day is administered to an adult individual for 1 to 12 months.
[506] 2) local route
[507] (a) The following nonionic water-in-oil creams are prepared:
[508] Compound of Example 9 0.100 g
[509] Mixture of emulsifiable lanolin alcohols, waxes and refined oils marketed by BDF under the name "eucerin" 39.900 g
[510] Methyl para-hydroxybenzoate0.075 g
[511] Propyl para-hydroxybenzoate0.075 g
[512] Sterile demineralized water
[513] The cream is applied to the psoriasis area skin 1 to 2 times per day for 1 to 12 months.
[514] (b) a gel is prepared by preparing the following formulation:
[515] 0.001 g of the compound of Example 28
[516] Erythromycin base 4.000 g
[517] Butylhydroxytoluene0.050 g
[518] 2.000 g of hydroxypropylcellulose sold by Hercules under the name "Klucel HF"
[519] Ethanol (95 ° Purity) Proper 100.00 g
[520] Depending on the severity of the condition to be treated, the gel is applied to dermatitis or acne area skin 1 to 3 times per day for 6 to 12 weeks.
[521] (c) The anti-sebum lotion is prepared by mixing the following ingredients together:
[522] 0.030 g of the compound of Example 12
[523] Propylene Glycol5.000 g
[524] Butylhydroxytoluene0.100 g
[525] Ethanol (pure 95 °) suitable amount100.000 g
[526] By applying the lotion twice per day to seborrheic scalp, a significant improvement is observed within 2 to 6 weeks.
[527] (d) A cosmetic composition for eradicating the harmful effects of sunlight is prepared by mixing the following ingredients together:
[528] 1.000 g of the compound of Example 7
[529] Benzylidene camphor 4.000 g
[530] Fatty acid triglycerides31.000 g
[531] Glyceryl Monostearate6.000 g
[532] Stearic acid2.000 g
[533] Cetyl alcohol1.200 g
[534] Lanolin 4.000 g
[535] Preservative 0.300 g
[536] Propylene Glycol2.000 g
[537] Triethanolamine0.500 g
[538] Air freshener0.400 g
[539] Deionized water 100.000 g
[540] The composition is applied daily to help eradicate light-induced aging.
[541] (e) The following nonionic oil-in-water creams are prepared:
[542] 0.500 g of the compound of Example 23
[543] Retinoic acid0.020 g
[544] Cetyl Alcohol4.000 g
[545] Glyceryl Monostearate2.500 g
[546] PEG-50 stearate2.500 g
[547] Karite Butter9.200 g
[548] Propylene Glycol2.000 g
[549] Methyl para-hydroxybenzoate0.075 g
[550] Propyl para-hydroxybenzoate0.075 g
[551] Sterile Demineralized Water Proper 100.000 g
[552] The cream is applied to the psoriasis area skin once or twice a day for 30 days for active treatment and indefinitely for maintenance treatment.
[553] (f) A topical gel is prepared by mixing the following ingredients together:
[554] Compound 50 of Example 19
[555] Ethanol43.000 g
[556] α-tocopherol0.050 g
[557] 0.500 g of carboxyvinyl polymer sold by the company "Goodrich" under the name "Carbopol 941"
[558] 3.800 g of triethanolamine in 20 wt% aqueous solution
[559] 9.00 g of water
[560] Propylene Glycol Proper 100.000 g
[561] Depending on the severity of the condition to be treated, the gel is applied to acne treatment 1-3 times per day for 6-12 weeks.
[562] (g) Hair loss prevention and hair growth lotion are prepared by mixing the following ingredients together:
[563] Compound 5 of Example 13
[564] 1.00 g of a compound sold under the name "Minoxidil"
[565] Propylene Glycol20.00 g
[566] Ethanol 34.92 g
[567] Polyethylene glycol (molecular weight = 400) 40.00 g
[568] Butylhydroxyanisole0.01 g
[569] Butylhydroxytoluene0.02 g
[570] 100.00 g of water
[571] The lotion is applied to the scalp suffering from hair loss for 3 months and indefinitely for maintenance treatment, once or twice a day.
[572] (h) Antiacne creams are prepared by mixing the following ingredients together:
[573] Compound 5 of Example 5
[574] Retinoic acid0.010 g
[575] 15.000 g of a mixture of glyceryl stearate and polyethylene glycol stearate (75 moles) sold under the name "Gelot 64" by the company "Gattefosse"
[576] 8.000 g of polyoxyethylenated phosphorus oil containing 6 moles of ethylene oxide, sold under the name "Labrafil M2130 CS" by the company "Gattefosse"
[577] Perhydrosqualene10.000 g
[578] Preservative
[579] Polyethylene glycol (molecular weight = 400) 8.000 g
[580] 0.050 g of disodium salt of ethylenediamine tetraacetic acid
[581] Purified Water Proper 100.000 g
[582] The cream is applied to the dermatitis or acne area skin 1 to 3 times per day for 6 to 12 weeks.
[583] (i) the following formulation is prepared to prepare an oil-in-water cream:
[584] 0.020 g of the compound of Example 14
[585] Betamethasone 17-Balerate0.050 g
[586] S-carboxymethylcysteine3.000 g
[587] 4.000 g of polyoxyethylene stearate (40 moles of ethylene oxide) sold by the company "Atlas" under the name "Myrj 52"
[588] 1.800 g of sorbitan monolaurate polyoxyethylated with 20 moles of ethylene oxide, sold under the name "Tween 20" by the company "Atlas"
[589] A mixture of glycerol mono- and distearate sold under the name "Geleol" by the company "Gattefosse" 4.200 g
[590] Propylene Glycol10.000 g
[591] Butylhydroxyanisole0.010 g
[592] Butylhydroxytoluene0.020 g
[593] Cetostearyl Alcohol6.200 g
[594] Preservative
[595] Perhydrosqualene18.000 g
[596] 4.000 g of a mixture of caprylic / capric triglycerides sold under the name "Miglyol 812" by the company Dynamit Nobel.
[597] Triethanolamine (99% by weight) 2.500 g
[598] Water volume 100.000 g
[599] The cream is applied twice a day to the skin of the inflammatory dermatitis site for 30 days.
[600] (j) The following oil-in-water creams are prepared:
[601] Lactic acid5.000 g
[602] 0.020 g of a compound of Example 8
[603] 4.000 g of polyoxyethylene stearate (40 moles of ethylene oxide) sold by the company "Atlas" under the name "Myrj 52"
[604] 1.800 g of sorbitan monolaurate polyoxyethylated with 20 moles of ethylene oxide, sold under the name "Tween 20" by the company "Atlas"
[605] A mixture of glycerol mono- and distearate sold under the name "Geleol" by the company "Gattefosse" 4.200 g
[606] Propylene Glycol10.000 g
[607] Butylhydroxyanisole0.010 g
[608] Butylhydroxytoluene0.020 g
[609] Cetostearyl Alcohol6.200 g
[610] Preservative
[611] Perhydrosqualene18.000 g
[612] 4.000 g of a mixture of caprylic / capric triglycerides sold under the name "Miglyol 812" by the company Dynamit Nobel.
[613] Water volume 100.000 g
[614] Applying the cream once a day helps to eradicate photo-induced or age aging.
[615] (k) The following anhydrous ointments are prepared:
[616] Compound 5 of Example 25
[617] Liquid Petroleum Jelly50.000 g
[618] Butylhydroxytoluene0.050 g
[619] 100 g of white petroleum jelly
[620] The ointment is applied twice a day for 30 days to the skin of the scaly dermatitis site.
[621] 3) intralesional pathway
[622] (a) the following composition is prepared:
[623] 0.002 g of the compound of Example 16
[624] 10 g of ethyl oleate
[625] In the treatment of malignant melanoma, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[626] (b) the following composition is prepared:
[627] Compound 50 of Example 10
[628] Olive oil 2 g
[629] In the treatment of basal cell carcinoma, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[630] (c) the following composition is prepared:
[631] Compound of Example 60.1 mg
[632] Sesame oil amount 2 g
[633] In the treatment of climax cell carcinoma, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[634] (d) the following composition is prepared:
[635] Compound of Example 2 0.001 mg
[636] 10 g of methyl benzoates
[637] In the treatment of colon carcinoma, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[638] 4) intravenous route
[639] (a) The following injectable lipid emulsions are prepared:
[640] Compound of Example 7 0.001 mg
[641] Soybean oil10.000 g
[642] Egg (egg) phospholipid1.200 g
[643] Glycerol2.500 g
[644] Suitable amount of water for injection100.000 g
[645] In the treatment of psoriasis, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[646] (b) the following injectable lipid emulsions are prepared:
[647] 0.010 g of a compound of Example 3
[648] Cottonseed oil10.000 g
[649] Soy lecithin0.750 g
[650] Sorbitol5.000 g
[651] DL, α-tocopherol0.100 g
[652] Suitable amount of water for injection100.000 g
[653] In the treatment of young children, the composition is injected into adult individuals at a frequency of 1 to 7 times per week for 1 to 12 months.
[654] (c) the following injectable lipid emulsions are prepared:
[655] Compound of Example 21 0.001 g
[656] Soybean oil15.000 g
[657] Acetylated Monoglycerides10.000 g
[658] Pluronic F-1081.000 g
[659] Glycerol2.500 g
[660] Suitable amount of water for injection100.000 g
[661] In the treatment of leukemia, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[662] (d) the following mixed micelle composition is prepared:
[663] 0.001 g of the compound of Example 29
[664] Lecithin16.930 g
[665] Glycolic acid8.850 g
[666] Suitable amount of water for injection100.000 g
[667] In the treatment of malignant melanoma, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[668] (e) the following cyclodextrin compositions are prepared:
[669] Compound of Example 110.1 mg
[670] 0.100 g of β-cyclodextrin
[671] 10.000 g of water for injection
[672] In the treatment of transplant rejection, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[673] (f) the following cyclodextrin compositions are prepared:
[674] 0.010 g of a compound of Example 4
[675] 0.100 g of 2-hydroxypropyl-β-cyclodextrin
[676] 10.000 g of water for injection
[677] In the treatment of kidney cancer, the composition is injected into adult subjects at a frequency of 1 to 7 times per week for 1 to 12 months.
[678] Example 31 Test Example for Assessing Biological Activity of Compounds of the Invention
[679] Reporter plasmid p240Hase-CAT comprising an expression vector of the human VDR receptor and a -1399 to +76 region of the rat 24-hydroxylase promoter cloned upstream of the coding frame of the chloramphenicol-acetyl-transferase (CAT) gene. In coexfection, VDR agonist activity was tested on HeLa cell lines. After 18 hours of coverage, the test product is added to the medium. After 18 hours of treatment, the CAT activity of the cell lysates is analyzed by ELISA test. Results are expressed as percentage of the effect normally observed with 10 ⁻⁷ M calcitriol.
[680] Agonist activity was confirmed in the coatfection system by determining the dose (AC50) needed to achieve 50% of the maximum activity of the product.
[681] Test compoundAC 50 (nM) Example 3470 Example 102045 Example 11291 Example 1646 Example 17194 Example 18133 Example 22451

权利要求:
Claims (15)
[1" claim-type="Currently amended] The compounds corresponding to formula (I), the optical and stereoisomers of the compounds of formula (I) as well as their salts:
[Formula I]
(In the meal,
-R ₁ represents a hydrogen atom, a CH ₃ radical or a radical-(CH ₂ ) _r -OR ₄ ,
-R ₂ represents a radical-(CH ₂ ) _s -OR ₅ (r, s, R ₄ and R ₅ have the meanings indicated below),
X-Y represents a bond selected from the bonds of the formulas a to d which can be read from left to right or vice versa:
[Formula a]
[Formula b]
[Formula c]
[Formula d]
(R ₆ and W have the meanings shown below),
Ar ₁ represents a ring of the formulas e to i:
[Formula e]
[Formula f]
[Formula g]
[Formula h]
[Formula i]
(R ₇ , R ₈ and R ₉ have the meanings shown below),
Ar ₂ represents a ring of the formulas j to n:
[Formula j]
[Formula k]
[Formula l]
[Formula m]
[Formula n]
(R ₁₀ , R ₁₁ and R ₁₂ have the meanings shown below),
R ₃ represents a radical of the formula:

(t, R ₁₃ , R ₁₄ and R ₁₅ have the meanings shown below),
R and s, which may be the same or different, are 1 or 2, and
R ₄ and R _5, which may be the same or different, represent a hydrogen atom, an acetyl radical, a benzoyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical or a tetrahydropyranyl radical,
R ₆ represents a hydrogen atom or a lower alkyl radical,
W represents an NH radical which may be substituted with an oxygen or sulfur atom, a CH ₂ radical, or a lower alkyl radical,
R ₇ and R _10, which may be the same or different, represent a hydrogen atom or a lower alkyl radical,
R ₈ , R ₉ , R ₁₁ and R ₁₂ , which may be the same or different, represent a hydrogen atom, a lower alkyl radical, a halogen atom, a radical —OR ₁₆ , a polyether radical, a CF ₃ radical, a NO ₂ radical, or one or Represents an amino radical which may be substituted with two lower alkyl radicals (R ₁₆ has the meanings indicated below),
t is 0 or 1,
R ₁₃ and R _14, which may be the same or different, represent a hydrogen atom, a lower alkyl radical, a cycloalkyl radical, a CF ₃ radical or a C ₂ F ₅ radical,
R ₁₅ represents a hydrogen atom, an acetyl radical, a trimethylsilyl radical, a tert-butyldimethylsilyl radical or a tetrahydropyranyl radical,
R ₁₆ represents a hydrogen atom or a lower alkyl radical).
[2" claim-type="Currently amended] 2. Compounds according to claim 1, characterized in that they are in the form of salts of inorganic or organic acids, in particular hydrochloric acid, sulfuric acid, acetic acid, fumaric acid, hemisuccinic acid, maleic acid or mandelic acid.
[3" claim-type="Currently amended] A compound according to claim 1 or 2, wherein the lower alkyl radical is selected from methyl, ethyl, isopropyl, tert-butyl and hexyl radicals.
[4" claim-type="Currently amended] The compound according to any one of claims 1 to 3, wherein the cycloalkyl radical corresponds to a cyclopropyl, cyclopentyl or cyclohexyl radical.
[5" claim-type="Currently amended] The compound according to any one of claims 1 to 4, wherein the halogen atom corresponds to a fluorine, chlorine or bromine atom.
[6" claim-type="Currently amended] The compound according to any one of claims 1 to 5, wherein the polyether radical corresponds to a methoxymethoxy, methoxyethoxy or methoxyethoxymethoxy radical.
[7" claim-type="Currently amended] A compound according to claim 1, which is taken alone or as a mixture from the group consisting of:
{5- [4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
{5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{2-hydroxymethyl-5- [4 '-(1-hydroxy-1-methylethyl) -2'-methylbiphenyl-3-yloxymethyl] phenyl} methanol
(5- {2- [3 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
{2-hydroxymethyl-5- [3 '-(1-hydroxy-1-methylethyl) -biphenyl-3-yloxymethyl] phenyl} methanol
{5- [4 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [3 '-(2-ethyl-2-hydroxybutyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) biphenyl-3-yl] -2-methyl-2-propanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylsulfanylmethyl] -2-hydroxymethylphenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{2-hydroxymethyl-4- [4 '-(1-hydroxy-1-propylbutyl) -2,2'-dimethylbiphenyl-3-yloxymethyl] phenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
(4- {3- [5- (1-ethyl-1-hydroxypropyl) -2-pyridyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -6,2', 6'-trimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2', 6'-dimethylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
1- {4- [3- (3,4-bis-hydroxymethyl-benzyloxy) phenyl] -2-thienyl} -1-propanol
(4- {3- [4- (1-ethyl-1-hydroxypropyl) -2-thienyl] phenoxymethyl} -2-hydroxymethylphenyl) methanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-ylmethoxy] -2-hydroxymethylphenyl} methanol
1- [3 '-(3,4-bis-hydroxymethyl-phenoxymethyl) -2-methylbiphenyl-4-yl] -1-propanol
{4- [4 '-(1-ethyl-1-hydroxypropyl) -3'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-4-yloxymethyl] -2-hydroxymethylphenyl} methanol
{4- [2'-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) -2-methyl-biphenyl-4-yl] -2,2-dimethyl-1-propanol
1- [3 '-(3,4-bis-hydroxymethyl-benzyloxy) -2-methylbiphenyl-4-yl] -2-methyl-1-propanol
{2-hydroxymethyl-4- [methyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] phenyl} methanol
[5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -4-methyl-2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -4-methyl-2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[2-hydroxymethyl-5- (2- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
(2-hydroxymethyl-5- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
[5- (2- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[2-hydroxymethyl-5- (2- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
(2-hydroxymethyl-5- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
[5- (2- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[2-hydroxymethyl-5- (2- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienyl} ethyl) phenyl] methanol
(2-hydroxymethyl-5- {5- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienylmethoxy} phenyl) methanol
[5- (2- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {5- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -3-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {4- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {4- [2-ethyl-4- (1-ethyl-1-hydroxypropyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[5- (2- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -5-methyl-2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {4- [4- (1-ethyl-1-hydroxypropyl) -2-methylphenyl] -5-methyl-2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[2-hydroxymethyl-5- (2- {4- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
(2-hydroxymethyl-5- {4- [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl] methanol
[5- (2- {4- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) -2-hydroxymethylphenyl] methanol
(5- {4- [ethyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} -2-hydroxymethylphenyl) methanol
[2-hydroxymethyl-5- (2- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienyl} ethyl) phenyl] methanol
(2-hydroxymethyl-5- {methyl [methyl (trifluorohydroxytrifluoromethylethyl) phenyl] -2-thienylmethoxy} phenyl) methanol
{5- [2'-ethyl-4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [4 '-(1-ethyl-1-hydroxypropyl) -2'-isopropyl-6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [2'-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) -6-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [ethylmethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{2-hydroxymethyl-5- [2'-isopropyl-6-methyl-4 '-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl) biphenyl- 3-yloxymethyl] phenyl} methanol
{5- [dimethylethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [6-ethyl-4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [4 '-(1-ethyl-1-hydroxypropyl) -6-methoxy-2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [6-tert-butyl-4 '-(1-ethyl-1-hydroxypropyl) -2'-methylbiphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
{5- [ethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
(2-Hydroxymethyl-5- [6-methoxy-2'-methyl-4 '-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl) biphenyl- 3-yloxymethyl] phenyl} methanol
{5- [dimethylethylmethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yloxymethyl] -2-hydroxymethylphenyl} methanol
(5- {2- [4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yl] ethyl} -2-hydroxymethylphenyl) methanol
(5- {2- [dimethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-yl] ethyl} -2-hydroxymethylphenyl} methanol
(5-{[4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-ylamino] methyl} -2-hydroxymethylphenyl} methanol
(5-{[dimethyl (trifluorohydroxytrifluoromethylethyl) -biphenyl-3-ylamino] methyl} -2-hydroxymethylphenyl} methanol
[5-({[4 '-(1-ethyl-1-hydroxypropyl) -6,2'-dimethylbiphenyl-3-yl] methylamino} methyl) -2-hydroxymethylphenyl] methanol
[5-({[dimethyl (trifluorohydroxytrifluoromethylethyl) biphenyl-3-yl] methylamino} methyl) -2-hydroxymethylphenyl] methanol.
[8" claim-type="Currently amended] A compound according to claim 1 having at least one, preferably all of the following characteristics:
R ₁ represents a CH ₃ or CH ₂ 0H radical,
R ₂ represents a CH ₂ 0H radical,
X-Y represents a bond of formula a or c,
R ₃ represents the radical C (R ₁₃ ) (R _l4 ) OH.
[9" claim-type="Currently amended] Use of a compound according to any one of claims 1 to 8 for the manufacture of a pharmaceutical product.
[10" claim-type="Currently amended] Use for the manufacture of a pharmaceutical product for the following treatment of a compound according to any one of claims 1 to 8:
Skin diseases associated with keratin disorders that occur on differentiation and proliferation, such as simple acne, scrim, multinucleated leukocytes, injections, crystalline cystic acne, clot acne, senile acne and secondary acne, such as daylight, drug associated or occupational acne;
Other types of keratinous disorders, such as ichthyosis, lamb's condition, Darier's disease, palmar keratosis, leukoplasias and vitiligo condition, and skin or mucous membranes (buccal);
Other dermatological diseases of inflammation and / or immunoallergic factors, with or without cell proliferation, in particular all forms of psoriasis that are skin, mucous membranes or mild psoriasis, and psoriasis rheumatism, or alternatively skin atopics such as eczema or respiratory atopy or otherwise Gingival hyperplasia;
All skin or epidermal proliferations of benign or malignant, and viral or other origin, such as proliferative warts, squamous warts and warty epidermal dysplasia, oral or flowering papillomas, T lymphomas and proliferation that can be induced by UV irradiation, Especially basal and stromal cell epithelial tumors, as well as any precancerous skin lesions such as keratinocytes;
Other dermatological diseases, such as immune dermatitis, such as lupus erythematosus, immune bullous, and collagen diseases such as scleroderma;
Skin diseases or general diseases of immunological factors;
Sebaceous dysfunction such as acne or seborrheic hyperplasia;
Skin disorders due to exposure to UV radiation, skin aging that is photoinduced or age aging, pigmentation and actinic keratosis, or any disease associated with age or light aging;
Scarring disorders or stretch marks;
Inflammatory diseases such as arthritis, dermatosis or any disease of overall viral origin such as Kaposi's syndrome;
Ophthalmic disorders, in particular keratosis;
Cancers or precancerous conditions of cancer that may appear or be induced by vitamin D receptors, such as breast cancer, leukemia, myelodysplastic syndromes and lymphomas, epithelial cell carcinoma and gastrointestinal cancers, melanoma and osteosarcoma;
Alopecia of various origins, in particular alopecia due to chemotherapy or radiation;
Immune diseases such as autoimmune diseases such as type 1 diabetes, multiple sclerosis, lupus and lupus type diseases, asthma, glomerulonephritis, selective dysfunction of the immune system such as AIDS, or immune rejection;
-Endocrine diseases;
Diseases characterized by abnormal treatment of intracellular calcium, and diseases involving calcium metabolism, such as muscle ischemia;
Vitamin D deficiency and other mineral homeopathic diseases in plasma and bone, such as rickets, osteomalacia, osteoporosis, renal dystrophy and parathyroid dysfunction, especially in postmenopausal women;
Cardiovascular diseases such as atherosclerosis or hypertension, as well as insulin-independent diabetes.
[11" claim-type="Currently amended] A pharmaceutical composition comprising, in a pharmaceutically acceptable support, at least one of the compounds as defined in any one of claims 1 to 8.
[12" claim-type="Currently amended] The composition according to claim 11, wherein the concentration of the compound (s) according to any one of claims 1 to 8 is 0.0001% to 5% by weight relative to the total weight of the composition.
[13" claim-type="Currently amended] Cosmetic composition, characterized in that, among the cosmetically acceptable supports, at least one of the compounds as defined in any one of claims 1 to 8 is included.
[14" claim-type="Currently amended] The composition of claim 13, wherein the concentration of compound (s) is 0.001% to 3% by weight relative to the total weight of the composition.
[15" claim-type="Currently amended] Use of the cosmetic composition as defined in claim 13 or 14 for body or hair hygiene.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US5716624A|1998-02-10|Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof

---

US4829080A|1989-05-09|Aromatic benzopyranyl and benzopyranyl compounds; their preparation; and their use in cosmetic compositions and human and veterinary medicine

---

JP2602633B2|1997-04-23|Vitamin D3 analog

---

JP2753300B2|1998-05-18|Aromatic esters and thioesters

---

EP0232199B1|1993-02-03|Aromatic benzamido compounds, process for their preparation and their use in human or veterinary medicine as well as in cosmetics

---

US6797731B2|2004-09-28|Resorcinol derivatives

---

EP1458697B1|2006-09-06|Biphenylmethyl-thiazolidinediones and analogues and their use as ppar-gamma activators

---

AU719311B2|2000-05-04|Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents

---

US5686586A|1997-11-11|Polycyclic aromatic derivatives, process for preparing the same and pharmaceutical and cosmetic compositions containing the same

---

CA1266646A|1990-03-13|Benzonaphtalenic derivatives, process for theirpreparation and uses as pharmaceutic and cosmeticagents

---

US5786379A|1998-07-28|Adamantyl-substituted biaromatic compounds and pharmaceutical/cosmetic compositions comprised thereof

---

EP0633245B1|1996-09-04|Vitamin D compounds and method of preparing these compounds

---

CA1256378A|1989-06-27|Pharmaceutical composition containing at least onenaphtalenic derivative as active principle

---

EP1692093B1|2008-11-19|Biphenyl derivatives useful as ligands that activate the rar receptors, process for preparing them and use thereof in human medicine and in cosmetics

---

DE3690187C2|1998-11-26|Naphthalene derivatives with retinoid activity, process for their preparation and pharmaceutical and cosmetic compositions containing them

---

DE3443231C2|1994-04-07|Polysubstituted naphthalene derivatives, process for their preparation and pharmaceutical and cosmetic preparations containing these compounds

---

US5929056A|1999-07-27|Vitamin D compounds and method of preparing these compounds

---

EP0679628B1|1998-04-22|Polyene derivatives, pharmaceutical and cosmetic composition containing them and their use

---

CA2348725C|2007-04-17|Vitamin d analogues

---

JPH0784437B2|1995-09-13|Heterocyclic retinoid

---

US6803382B2|2004-10-12|Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof

---

US20030073745A1|2003-04-17|Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias

---

US7148245B2|2006-12-12|Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them

---

RU2149863C1|2000-05-27|Triaromatic compounds, compositions containing thereof and their use

---

HU198183B|1989-08-28|Process for producing tetrahydronaphthalene derivatives and pharmaceutical compositions comprising these compounds

同族专利:

---

公开号 | 公开日

---

DE60011669D1|2004-07-22|

---

JP2003514892A|2003-04-22|

---

JP3822106B2|2006-09-13|

---

DK1235777T3|2004-09-20|

---

SE1235777T5|2004-09-21|

---

CA2392165C|2008-08-26|

---

AU2522201A|2001-06-04|

---

ZA200203475B|2003-04-01|

---

WO2001038303A2|2001-05-31|

---

US6831106B1|2004-12-14|

---

CN1213980C|2005-08-10|

---

BR0015924A|2002-08-06|

---

MXPA02005175A|2003-01-28|

---

CN1616452A|2005-05-18|

---

CN100522943C|2009-08-05|

---

WO2001038303A3|2002-01-17|

---

EP1235777B1|2004-06-16|

---

FR2801305B1|2002-12-06|

---

RU2237651C2|2004-10-10|

---

AU767399B2|2003-11-06|

---

PT1235777E|2004-11-30|

---

DE60011669T2|2005-06-30|

---

AT269289T|2004-07-15|

---

CN1423627A|2003-06-11|

---

PL364768A1|2004-12-13|

---

PL207046B1|2010-10-29|

---

ES2223642T3|2005-03-01|

---

AR043279A1|2005-07-27|

---

KR100599069B1|2006-07-12|

---

TR200401603T4|2004-08-23|

---

CA2392165A1|2001-05-31|

---

EP1235777A2|2002-09-04|

---

SE1235777T3|2004-08-03|

---

FR2801305A1|2001-05-25|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1999-11-24|Priority to FR99/14781

---

1999-11-24|Priority to FR9914781A

---

2000-11-22|Application filed by 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨.

---

2002-07-10|Publication of KR20020056944A

---

2006-07-12|Application granted

---

2006-07-12|Publication of KR100599069B1

优先权:

---

申请号 | 申请日 | 专利标题

---

FR99/14781|1999-11-24|

---

FR9914781A|FR2801305B1|1999-11-24|1999-11-24|Vitamin d analogs|